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There is great potential to use gold nanoparticles as a method of assembling multiple 
probes into one targeted imaging agent. This thesis describes the co-coating of gold 
nanoparticles with different combinations of lanthanide complexes and peptides, and 
the effect of this co-coating on the photophysical properties of the lanthanide 
complexes has been examined. A photophysical study of europium (III) ions binding 
to two surface active peptides in solution is presented and the ability of these 
peptides to bind the europium ions whilst tethered to gold nanoparticles is discussed. 
The peptides selected for this study contain two thiols for stronger binding to the gold 
nanoparticle surface. Lanthanide complexes with a diethylenetriaminepentaacetic 
acid (DTPA) binding motif were prepared and attached to gold nanoparticles with 
different nuclear localisation signal peptides to investigate their photophysical 
properties and their potential as a cellular imaging agent has been demonstrated. 
The effects on the photophysical properties of the lanthanide complexes in the 
presence of different peptides on gold nanoparticles have also been compared.   
The co-coating of gold nanoparticles with europium and gadolinium complexes is 
also introduced, with the combinations on gold nanoparticles giving rise to an 
interesting energy transfer effect between the two different lanthanide complexes. 
These nanoparticles have the potential to be used as a multi-modal imaging agent for 
luminescent and magnetic resonance imaging.  
The synthesis of an azo-dye has been undertaken and its ability to bind and sensitise 
the near-infrared lanthanides neodymium (III) and ytterbium (III) has been 
demonstrated. It was found to form complexes with these lanthanides, and the high 
molar absorption coefficients in the visible region allows for excitation at wavelengths 
up to 500 nm. 
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1 The lanthanide elements 
The lanthanides are the group of 15 elements in the periodic table from lanthanum to 
lutetium with the atomic numbers 57-71. They are distinguished by their electronic 
configuration [Xe] 4f n, n = 0-14, with the occupation of the 4f orbitals. The chemical 
properties, particularly oxidation states of the lanthanides are similar across the 
series as the lanthanides typically exist as trivalent Ln3+ in aqueous solution.1  
The atomic radii of the lanthanides decrease across the series, due to the directional 
and dispersed nature of the 4f orbitals, which means that the addition of electrons to 
the orbital does not counteract the effect of the increased nuclear charge. This is 
often referred to as the lanthanide contraction. The large ionic radii of lanthanides 
allow for coordination numbers greater than 6, with the lanthanides typically 
exhibiting coordination numbers around 8 and 9. 
Luminescence from lanthanide(III) ions is caused by the electronic rearrangements 
within the 4f subshells. Relaxation of an f-electron from the excited state to the 
ground state causes a release of energy in the form of a photon of light. Lanthanide 
ions have very weak absorption coefficients due to the parity-forbidden f-f transitions. 
This is as stated by the Laporté selection rule, which prohibits the redistribution of 
elections within the 4f subshells. Their weak absorption coefficients can also be 
attributed to the shielding of the 4f orbitals by the filled 5p6 6s2 sub-shells, which 
results in little interaction with the surrounding chemical environment. They exhibit 








Figure 1.1: Electronic excited-state energy level diagram for the lanthanides. n is the f-orbital electron 





Lanthanide luminescence is caused by the radiative relaxation of an excited-state 
f-electron to the ground state. The wavelengths at which this emission is observed is 
dependent upon the energy gap between the excited state and the ground state and 
is characteristic for each lanthanide. Emission of lanthanides can be observed in the 




europium, terbium, samarium and dysprosium(III) is observed in the visible region, 
whilst neodymium, ytterbium and erbium(III) all exhibit luminescence in the near-
infrared region. Gadolinium(III) emits in the UV region and is more difficult to excite 
than the other lanthanides because it has a higher energy excited state which 
requires non-conventional excitation (i.e. excitation at low temperature).  
Lanthanides(III) ions exhibit long luminescence lifetimes and characteristic narrow 
emission bands. The weak absorption coefficients for direct excitation as a result of 
the parity-forbidden f-f absorption transitions can be overcome by the complexation 
of lanthanides within close proximity to an antenna which is able to absorb energy 
and transfer it to the lanthanide ion. This is shown by the absorption, energy transfer, 











The energy transfer mechanism for the sensitisation of lanthanides involves the 
intramolecular energy transfer from the triplet state of the organic chromophore to the 
excited state of the lanthanide ion.  
A great deal of research has focussed on the development of highly stable lanthanide 
complexes designed with efficient chromophores for indirect lanthanide excitation. 
 
 
2 Lanthanide ion coordination 
Many binding motifs have been investigated for the binding of lanthanide ions, and 
have been reviewed extensively within the literature.1, 6-10 Ln3+ are classified as hard 
acids by the Pearson scheme,11 and coordinate hard donors such as oxygen and 
nitrogen atoms. Lanthanides ions exist in a hydrated form, which means these hard 
donors are required to displace molecules of water from the inner coordination 
sphere. Coordination of lanthanide ions can be achieved by coordination with 
polydentate chelating ligands7, 12 and macrocycles6, 8, 13-16 or alternatively 
encapsulation within cryptands.5, 17 Designing a chelating ligand for lanthanide ions 
should be based on several key features, such as the inclusion of a chromophore 
with an excited energy state suitably close to the lanthanide acceptor state to allow 
intramolecular energy transfer to occur but not too close that back energy transfer 
occurs.17 The chelating ligand should also be stable and chemically inert, particularly 
for biological applications in which the release of the lanthanide ion from the 
chelating ligand or an exchange with biological cations such as Ca2+ could raise 
issues with toxicity via transmetallation. Exclusion of water molecules from the inner 




lanthanides to specific bond oscillators (e.g. O-H bonds), which can cause quenching 
by non-radiative decay.  
This effect has been exploited to calculate the number of inner-sphere water 
molecules (q) using the equation: 
 
q = A(kH – kD) 
 
Where A is a proportionality constant specific to each individual lanthanide 
and kH and kD are the rates of luminescence decay (reciprocal observed 
luminescence lifetime) measured in protonated and deuterated solvents 
respectively.18 
 
Chelating ligands based on diethylenetriaminepentaacetic acid (DTPA) are widely 
studied for their ease of modification for various applications (figure 1.3). They are 
known to bind strongly to lanthanide ions, and can be modified with varying degrees 
of functionality to give either mono-amide or bis-amide complexes. Preparation of 
these mono and bis-amide complexes can be achieved by a condensation reaction of 







Figure 1.3: Structures of basic DTPA derivatives 
 
 
The ability of these complexes to chelate lanthanide ions, and the simple procedure 
for modification of these chelates with chromophores and other functionalising 
groups make them desirable for use as bifunctional lanthanide chelating ligands.  
 
 
3 Luminescent lanthanide complexes for cellular imaging 
The unique photophysical properties of lanthanides have been exploited for the use 
as cellular probes. Emission from lanthanide(III) ions elicited by the antenna effect 
generally have large Stokes shift as the energy transfer is mediated by a number of 
energy states. This allows the emission to be easily distinguished from the excitation 
source.   
The long luminescent lifetimes of lanthanide complexes can be utilised for cellular 












observed from organic molecules within the cells usually has only very short-lived 
lifetimes which are in the nanosecond range. Thus the emission can be monitored 




Figure 1.4: Principle of time-gated spectroscopy 
 
 
There have been many examples of lanthanide cellular probes in the literature,4, 9, 10, 
15, 19-25 using different lanthanides to produce complexes that emit either in the the 
visible or near infrared regions for detection by luminescence microscopy. 
Lanthanide complexes are also heavily employed as contrast agents for magnetic 
resonance imaging (MRI),12 with some gadolinium complexes being commercially 
available for clinical use as contrast agents such as the gadolinium(III) complex 





3.1 Visible emitting lanthanide complexes 
Europium and terbium(III) complexes are commonly studied for use as cellular 
imaging probes due to them possessing longer luminescence lifetimes than their 
near-infrared counterparts. The cellular uptake of some macrocyclic lanthanide 
complexes has been thoroughly investigated by Parker et al.15, 20, 25 The structure of 
the complexes was found to contribute to their sub-cellular localisation. Different 
complexes containing tetraazatriaphenylene and azaxanthone chromophores were 
found to localise in four distinct sub-cellular regions: lysosomes, mitochondria, 











Bünzli et al. reported the use of lanthanide bimetallic triple-stranded helicates as 
imaging probes.24, 26, 27 The water soluble europium helicates were found to be taken 
up by human cervical adenocarcinoma cell line (HeLa) and were visible in the 







cytoplasm of the cells when examined by confocal microscopy. These helicates have 
a reported quantum yield of 18 ± 2 %.24 
 
 
Figure 1.6: Structure of ligand which forms helicates with lanthanide ions at a ratio of 2 lanthanides to 
3 ligands. Confocal microscopy images of RPMI-1640 incubated with various concentrations of 





One of the drawbacks to lanthanide complexes that emit in the visible region is that 
the human body contains biological molecules that can absorb in the visible region, 
such as haemoglobin which can affect the probes’ ability as an imaging agent. 
Furthermore due to the higher energy excited state of the visible lanthanides, the 
energy required to populate the lanthanide excited state is much higher which limits 
the excitation wavelengths required to wavelengths in the UV region. Such excitation 




absorbed by biological molecules, which limits the effectiveness of the lanthanide 
complex. Near-infrared lanthanides have excited states which are lower in energy, 
making it possible for the use of wavelengths in the visible region.28 Therefore work 




3.2 Near-infrared emitting lanthanide complexes 
Lanthanide complexes that emit in the near-infrared are desirable for use as cellular 
probes, as near-infrared light is able to penetrate skin and other tissue.29 Biological 
molecules absorb in the UV region, thus limiting the depth at which shorter 
wavelengths of light can penetrate.30 Emission in the near-infrared allows for the use 
of a chromophore which can be excited at higher wavelengths within the visible 
region. Tissue has minimal absorption at wavelengths greater than 600 nm, therefore 
the signal to noise ratio is greatly improved with the use of near-infrared probes.30 
There have been different strategies for the sensitisation of near-infrared lanthanides, 
with the use of chelating ligands with attached organic chromophores16, 31-34 or 






Figure 1.7: Structures of some reported near-infrared emitting complexes.  1: Fluorinated 
imidodiphosphinate ligand for sensitisation of Ln = Nd, Sm, Eu, Gd, Tb, Dy, Er, Yb.
31
 2: Anthraquinone 
chromophore attached to a tetraaza macrocyclic ligand for Ln = Nd, Gd, Er, Yb.
33
 3: 2-(2-
pyridyl)benzimidazole unit with an anthracene group for Ln = Nd, Gd, Er, Yb.
16
 4: Phenanthridine 





The near-infrared lanthanide complexes typically exhibit shorter luminescence 
lifetimes than the visible lanthanides such as terbium and europium. A fluorinated 
imidodiphosphinate ligand was reported to give long luminescence lifetimes for the 
near-infrared lanthanides neodymium, ytterbium and erbium of 44 µs, 741 µs and 
1                                                2 




1111 µs respectively (figure 1.7, structure 1).31 The design of this compound was 
based on the need for a hydrophobic shell around the lanthanide, to minimise the 
coordination of solvent molecules to the lanthanide ion which can cause quenching.40  
Near-infrared complexes have also been developed with chromophores that can be 
excited in the visible region, such as anthraquinone, anthracene and phenanthridine 
complexes (figure 1.7, structures 2,3 and 4).16, 33, 34 
 
 
3.3 Lanthanide complexes as MRI contrast agents 
The paramagnetic properties of gadolinium(III) have been exploited for use as 
contrast agent for magnetic resonance imaging. Magnetic resonance imaging (MRI) 
is a powerful diagnostic technique for imaging anatomical structures of the body, and 
is useful for detecting diseased soft tissue such as tumours.41 The technique relies 
on the enhancement of relaxation of water protons in a magnetic field by use of a 
contrast agent.42 Gadolinium is known to enhance T1 relaxivity, the longitudinal 
relaxation time of surrounding water molecules.43 Gadolinium(III) ions are toxic and 
therefore cannot be administered directly, therefore the design of gadolinium contrast 
agents have to incorporate a strong chelating ligand to bind the ions. The structure of 
the chelating ligand should also allow for a free coordination site for the coordination 
at least one water molecule for exchange with surrounding water molecules. Some 
examples of commercially available gadolinium contrast agents are shown in 












Each of the commercially available gadolinium chelates shown in figure 1.8 have 
similar relaxivity r1 at 37
oC of 3.5-3.8 mM−1s−1 (20 MHz).41 These chelating ligands 
are highly stable (K = 1015),44 which means that when used as contrast agents they 
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4 Gold nanoparticles 
Gold nanoparticles’ unique optical properties, large surface area and biocompatibility 
make them highly desirable in the development of cellular probes. Gold nanoparticles 
of different sizes can be prepared easily by the reduction of a gold salt with a 
reducing agent such as citrate.45, 46 The reduction of HAuCl4 in water with citrate 
leads to the formation of gold nanoparticles stabilised by a weakly bound shell of 
anionic citrate, which remain mono-dispersed in solution due to electrostatic 
repulsion between the particles.47 The citrate ions on these gold nanoparticles can be 
readily exchanged with thiol-containing ligands that form stronger bonds to the gold 
surface, to form sterically stabilised gold nanoparticles.48 Citrate reduction of gold 
typically produces stable monodisperse gold nanoparticles, and different size 
nanoparticles between 10-150 nm can be prepared by adjusting the concentrations 
of starting reagents.45, 46 Small particles of 1-3 nm can be prepared by the two phase 
transfer method reported by Brust et al.49 Briefly, gold salt is transferred from 
aqueous phase to organic phase with tetraoctylammonium bromide and is then 
reduced by sodium borohydride in the presence of an alkanethiol. This leads to gold 
nanoparticles stabilised in the organic phase with alkanethiols. 
Gold nanoparticles adhere to Mie theory,50 where an electromagnetic frequency 
induces a resonant coherent oscillation of free electrons at the nanoparticle 
surface.51 This is called the surface plasmon resonance (SPR). The absorption of 
gold nanoparticles is within the visible range, with 13 nm citrate-stabilised particles 
characteristically exhibiting a SPR band at approximately 520 nm. The optical 
properties of gold nanoparticles can vary depending on the size, shape and 




modified with fluorophores,53, 54 peptides,55-60 antibodies and other biologically 
relevant molecules61 through the formation of gold-sulphur bonds. Gold nanoparticles 
provide a large surface area for the assembly of multiple probes and functionalising 
moieties. The functionalisation of gold nanoparticles can be monitored by changes in 
the SPR band observed by UV-Vis spectroscopy.  
Gold nanoparticles have excellent light scattering abilities, and can used in imaging 
by a number of different techniques. Transmission electron microscopy (TEM) is the 
most commonly used technique for imaging which exploits the high atomic weight of 
gold.51 The scattering properties can be imaged by dark-field microscopy, 
fluorescence microscopy and X-ray tomography.62 Gold nanoparticles are also ideal 
for intracellular imaging using surface-enhanced Raman scattering (SERS) as they 




5 Gold nanoparticles functionalised with lanthanides 
Gold nanoparticles have been widely developed as scaffolds for the delivery of 
multiple probes into cells. Gold nanoparticles are chemically inert within the body and 
provide a large surface area for the assembly of many functionalising moieties.64 
Therefore attaching lanthanide complexes to gold nanoparticles is desirable to aid 
the delivery of a larger concentration of the imaging probe into cells. Lanthanide 
coated gold nanoparticles have received increasing attention in recent publications.65-
72 Initial reports on the functionalisation of gold nanoparticles with lanthanide 




the gold nanoparticle. Lanthanide coated gold nanoparticles have been developed for 
different applications, such as sensors for metal ions,65 pH,72 anions and small 
molecules.69, 71 Gunnlaugsson et al. developed an assay utilising lanthanide 
complexes (1.Eu; figure 1.9A) on gold nanoparticles for the detection of biologically 
significant phosphate anions such as Flavin monophosphate.71 The assay works by 
the displacement of a sensitising antenna from the lanthanide complex by the 
phosphate leading to quenching of the lanthanide emission. 
 
 
Figure 1.9: (A) 1.Eu ligand; (B) β-diketone antennae; which upon excitation causes the 1.Eu ligand to 
become highly luminescent (C) Flavin monophosphate displaces the antennae from the 1.Eu ligand. 
  
 
Lanthanide nanoparticles have also been developed as cellular imaging probes.66-68, 
71 Europium diethylene triamine pentaacetic acid (DTPA) complexes (figure 1.10A) 
have been tethered to gold nanoparticles and were found to exhibit the characteristic 
red luminescence of Eu(III).67 Further investigations with these europium coated gold 
nanoparticles found that they could be successfully imaged and their intracellular 
distribution monitored by high-resolution synchrotron x-ray fluorescence 




(figure 1.10B) and a pH low insertion peptide (pHLIP) was found to promote the 
uptake of gold nanoparticles into platelets at pH 6.5.68  
 
 









6 Peptide coated gold nanoparticles 
Peptides are small chains of amino acids, which are often studied for biological 
applications. Typically they are used for targeting specific biomarkers or receptors in 
cells,73 as well as delivering molecules and imaging agents into the cell.74-76 Peptides 
have been modified with lanthanides for various biological applications to take 
advantage of their biocompatibility in the delivery of luminescent lanthanide probes.76-
78 More recent work has seen peptides being utilised for stabilising gold 
nanoparticles. The rational design of the small peptide CALNN reported by Fernig et 




highly stable and water soluble. 79 Further research into peptides has seen a rise in 
their use for the delivery of nanoparticles into cells.55, 56, 68, 80 
 
 
6.1 Cell Penetrating Peptides 
Cell penetrating peptides (CPP) are of particular interest due to their ability to deliver 
nanoparticles and other payloads into cells.60, 81 These peptides are short sequences 
of amino acids that are believed to be internalised via receptor- and endocytosis- 
independent mechanisms,82 although the mechanisms are not fully understood and 
cause a lot of debate within literature.83 Various different CPPs have been reported in 
recent years such as TAT60, 84, 85 and sweet arrow peptide.56 The peptide TAT is a 
particularly well reported peptide, which has been used to modify many different 
types of nanoparticles for cellular delivery such as gold nanoparticles, magnetic 
nanoparticles (e.g. iron oxide) and quantum dots.60 Further examples are given in 
table 1.1. 
 
Peptide Sequence Reference 
Tat GRKKRRQRRR 60, 84, 85 
Penetratin RQIKIWFQNRRMKWKK 85, 86 
Transportan GWTLNSAGYLLGKINLKALAALAKKIL 87 
Sweet arrow peptide (VRLPPP)3 
56 






6.2 Nuclear localisation signals 
One particular class of cell penetrating peptides are nuclear localisation signals 
(NLS), which are of interest as they are able to cross the nuclear membrane and 
enter the cell nucleus. The delivery of targeted molecules into the nucleus is 
desirable for cellular imaging58, 59 and the delivery of drugs and biologically active 
molecules.55 They are particularly useful for targeting DNA and gene silencing, which 
requires access to the nucleus. They have also been tethered to gold nanoparticles 
to allow them to pass through the nuclear membrane into the nucleus of cells.59 A 
study into the cellular trajectories of peptides on gold nanoparticles has revealed that 
two nuclear localisation signals are able to enter the nucleus of some cell lines.59 The 
peptide CGGFSTSLRARKA tethered to gold nanoparticles were found to localise in 
the nucleus of HeLa cells, but not 3T3/NIH or HepG2 cells. The peptide 
CKKKKKKGGRGDMFG however was found to enter HepG2 cells and target the 
nucleus. The ability of these peptides to deliver gold nanoparticles into the nucleus 
allows for great potential to exploit the large surface area of nanoparticles for delivery 
of multiple probes and therapeutics. 
 
 
6.3 CALNN coated gold nanoparticles 
Gold nanoparticles can be translocated into cells via the attachment of peptides to 
the nanoparticle surface. Small peptides have been designed for the preparation of 
highly stable water-soluble gold nanoparticles.88 The peptide CALNN consists of a 
cysteine which provides sulphur for attachment to gold nanoparticles. The alanine 




promote the self-assembly of the peptide. The two asparagine amino acids are 
hydrophilic, which aids in the solubility of the nanoparticles. The peptide CALNN and 
longer derivatives of the peptide have been used in the delivery of gold nanoparticles 
into cells.57, 85, 89 Wang et al. reported the cellular uptake of gold nanoparticles coated 
in the pentapeptide CALNN and an arginine-rich derivative CALNNR8.
57 It was found 
that coating gold nanoparticles with just CALNNR8 localised in the endoplasmic 
reticulum, whilst co-coating gold nanoparticles with CALNN and CALNNR8 were able 
to target the nucleus. Brust et al. investigated the effect of the cell penetrating 
peptides TAT (AGRKKRRQRRR) and Pntn (GRQIKIWFQNRRMKWKK) and the 
nuclear localisation signal (GGFSTSLRARKA) appended to CALNN peptide on gold 
nanoparticles.89 The predominant finding with the gold nanoparticles coated with the 
cell penetrating peptides TAT and Pntn was that the uptake into cells was mediated 
by endocytosis. Upon incubation of cells with gold nanoparticles coated with TAT, 
Pntn and NLS, it was observed that the nanoparticles were present in the cytosol, 
endosomes and in the nucleus. Further groups of nanoparticles were found near 
damaged endosomes, which suggests that the particles coated in this combination of 
peptides are capable of disrupting endosomal morphology. From these studies,the 
mechanism of uptake of peptide coated gold nanoparticles is not fully understood. 
CALNN stabilised gold nanoparticles have also been investigated as colorimetric 
sensors of various biologically relevant molecules such as Heparin,90 Abscisic acid91 






7 Multi-modal nanoparticles for imaging 
The development of agents able to serve multiple functions is desirable to allow the 
use of two or more imaging techniques or theragnosis for both imaging and 
therapy.94 Gold nanoparticles are particularly useful for multi-modal imaging due to 
their unique optical properties. However with further surface modification, gold 
nanoparticles can be altered to provide different properties for imaging and 
therapeutics. Gold nanoparticles have been modified with various anti-cancer drugs 
for treatment95 and siRNA for gene silencing.96 The quenching properties of gold 
nanoparticles have also been widely investigated, with fluorescent molecules being 
quenched in close proximity to the gold surface. The release of these molecules from 
the nanoparticle surface, which can be triggered by the presence of certain proteins97 
or light activation,98 causes a fluorescence enhancement.  
Gold nanoparticles have been modified with gadolinium complexes for potential use 
as a MRI contrast agent.99-102 A gadolinium complex consisting of DTPA conjugated 
to 4-aminothiophenol has been reported on gold nanoparticles as a MRI contrast 
agent. The structure of this complex is similar to the europium complex shown in 
figure 1.10A. The complex alone and on the gold nanoparticles exhibit higher r1 
relaxivity than that of the commercially available contrast agent Omniscan®. The r1 
value of the gadolinium complex on gold nanoparticles per [Gd] was reported as 
10.0 mM-1s-1, whilst the free gadolinium complex was lower at 6.3 mM-1s-1 and the 
Omniscan® was lower still at 3.3 mM-1s-1. The gadolinium coated gold nanoparticles 
have also been presented as potential computed tomography (CT) contrast agents. 
Other DTPA gadolinium complexes have been reported on gold nanoparticles as 




Gold nanoparticles have shown great promise in therapeutic applications using 
hyperthermic treatment. Upon exposure to laser irradiation, gold nanoparticles and 
nanorods begin to heat up which damages the cells in the vicinity. El Sayed et al. 
have reported selective photo-thermal therapy using gold nanoparticles with 
conjugated antibodies.104 By conjugating anti-epithelial growth factor receptor 
(Anti-EGFR) to gold nanoparticles, the nanoparticles can be used as a selective 
targeting and therapeutic agent. The nanoparticles were incubated with three 
epithelial cell lines, two malignant and one benign, then treated with a continuous 
visible argon ion laser at 514 nm. The malignant cells required less energy to kill the 
cells than the benign cells after incubation with the anti-EGFR gold nanoparticles, 
suggesting that these particles selectively target the malignant cells and offer 
opportunity for targeted photothermal therapy. 
 
 
8 Thesis outline 
The large surface area of gold nanoparticles makes them ideal scaffolds for the 
assembly of multiple probes for a variety of applications. Lanthanide complexes with 
their unique photophysical properties, such as long luminescent lifetimes and large 
Stokes shifts from the excitation source make them suitable as cellular imaging 
probes. This thesis describes the co-coating of gold nanoparticles with lanthanide 
complexes and targeting peptides for the development of targeting luminescent 
imaging probes. A photophysical study of europium (III) binding to two different 
peptides in solution, and the ability of these peptides to bind europium (III) ions whilst 




a DTPA binding motif were prepared and attached to gold nanoparticles with different 
nuclear localisation signal peptides to investigate their photophysical properties and 
their potential as a cellular imaging agent in chapter 3. Whilst DTPA complexes have 
been used previously to coat gold nanoparticles, 66-68, 100, 101 the lanthanide 
complexes selected for this study have not previously been studied with peptides on 
gold nanoparticles. The comparison of the photophysical effects of the same peptide 
sequences with different thiol-containing terminal group has also been presented.  
Chapter 4 introduces the co-coating of gold nanoparticles with europium and 
gadolinium complexes, with the combinations on gold nanoparticles giving rise to an 
interesting energy transfer effect between the two different lanthanide complexes. 
These co-coated gold nanoparticles were designed as a potential multi-modal 
luminescent and magnetic resonance imaging agents, utilising the photophysical and 
paramagnetic properties of the europium (III) and gadolinium (III) complexes.  
The near-infrared lanthanides have recently attracted attention as cellular probes as 
near-infrared light can readily penetrate skin and tissue. The development of an azo-
dye for sensitisation of the near-infrared lanthanides ytterbium (III) and neodymium 
(III) is discussed in chapter 5. The azo-dye was chosen for its high molar absorption 
coefficient in the visible region due to its extensive conjugation, which allows for 
excitation at wavelengths up to 500 nm. The azo-dye was found to form a complex 
with the lanthanide ions in a ratio of 3:1, exhibiting the characteristic emission of both 
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Lanthanide binding peptides and peptide coated gold nanoparticles 
 
1 Introduction 
Peptides have been utilised as vehicles for the delivery of luminescent probes into 
cells for targeting and monitoring specific protein-peptide interactions. Peptides that 
are able to bind lanthanides are particularly well studied due to their desirable 
photophysical properties, such as large Stokes shift, emission signal in the visible or 
near-infrared and luminescence lifetimes in microsecond to millisecond range.1, 2 The 
design of these lanthanide binding peptides are strongly dependant on two key 
features, firstly a ligating site to bind the lanthanide ion and a chromophore in close 
proximity to the ligating site to allow for the excitation of the lanthanide. The ligating 
sites can be designed based on the structural organisation of the peptide using the 
naturally occurring amino acids,3, 4 or modification of the peptide to incorporate a 
podand or macrocyclic structure (figure 2.1).5-8 Figure 2.1 shows two strategies of 
lanthanide for peptide labelling with lanthanide binding tags.3 The first strategy 
involves the chemical modification of the peptide by targeting certain amino acids 
with groups that can be easily modified such as cysteine which contains sulphurs. 
The second strategy is the encoding of the lanthanide binding tag at DNA level, 
leading to the expression of proteins with the lanthanide binding tag located on the 
N-terminus or C-terminus or alternatively located in a loop within the protein 
structure.3 The similar reactivity of the lanthanides allows for the use of non-
luminescent lanthanides for MRI imaging,9 NMR analysis of structural information10 or 
X-ray structural elucidation.11 For this reason, lanthanide binding peptides are widely 





Figure 2.1: Strategies for labelling peptides with lanthanides. (a) Modification of peptide with a 
synthetic lanthanide chelator. Chemical modification can occur between a reactive group (star) and 
cysteines (shown here) or other amino acids. LBT peptides may also be linked to the target protein by 
chemical modification of target cysteines. (b) Peptide-based lanthanide-binding ion tags (red) are 
encoded at the DNA level and fused to either the N-terminus or C-terminus of the target protein or into 
a loop.Figure reproduced from reference 3 
 
 
Gold nanoparticles are widely researched for their biomedical applications, as they 
provide a suitable platform for the delivery of multiple probes into cells. Due to the 
large surface area of gold nanoparticles, the surface can be functionalised with many 
different functional molecules. Peptide coated nanoparticles in particular are of 
interest in their potential applications in cellular binding and delivery.12-14 Certain 
peptide sequences have been found to translocate cell membranes and deliver 
functionalising moieties into cells.15 Combining lanthanides and peptides onto gold 





Work within our group has previously utilised lanthanide complexes on gold 
nanoparticles as cellular probes.16 The combination of a europium complex and a pH 
low insertion peptide (pHLIP) has been found to deliver the luminescent gold 
nanoparticles into platelets in a pH dependant manner.17 At pH above 7 the pHLIP 
peptide exhibits an unstructured formation and loosely associates with the cell 
membrane. At low pH, the peptide forms an alpha-helix across the lipid bilayer and 
inserts across the cell membrane (figure 2.2).  
 
 





In this chapter, a peptide has been designed and synthesised based on the peptide 
CALNN which is known to stabilise gold nanoparticles in aqueous solutions.18 The 
peptide ThioALNN has been found to bind lanthanide ions both in solution and also 




their ability to bind lanthanides in solution and on nanoparticles. The peptides 











2 Results and Discussion 
 
2.1 Synthesis and characterisation of ThioALNN peptide and Citrate.Au 
ThioALNN peptide was designed based on the peptide CALNN, which has been 
found to stabilise gold nanoparticles in aqueous solutions.18 The addition of a thioctic 
acid on the end of the peptide provides two sulphurs for stronger binding to gold 
nanoparticles. The peptide was prepared using FMOC-based solid-phase peptide 
synthesis, and purified by HPLC. The peptide was characterised by MALDI-TOF 
mass spectrometry, which showed a peak at 641 corresponding to the sodium 
adduct of the final peptide. A peak was also present at 643, suggesting that the 
peptide was also present in the reduced form. ThioALNN peptide was characterised 
by UV-Vis spectroscopy, which showed a single peak with a λmax at 203 nm.  
The gold nanoparticles prepared for this study were citrate stabilised gold 
nanoparticles (Citrate.Au). They were chosen as the preparation is a simple 
one-step synthesis to give stable and monodisperse nanoparticles of uniform size 
and shape in aqueous solution. Citrate.Au were prepared by the well-established 
citrate reduction of HAuCl4 giving monodisperse gold nanoparticles approximately 
13 nm in diameter (figure 2.4A). The deep red colloid gives the expected profile by 
UV-Vis spectroscopy with a λmax at 521 nm (figure 2.4B), characteristic of the surface 
plasmon resonance band (SPR) of nanoparticles of this size. 
The surface modification of Citrate.Au can be easily achieved by the formation of 
gold/sulphur bonds on the surface of the nanoparticles. The addition of peptides or 
any other moieties containing sulphur groups into Citrate.Au can be monitored by 




nanoparticles gives rise to changes in the SPR band, which is sensitive to changes in 
the surface chemistry of the gold nanoparticles.  
 
 
Figure 2.4: Characterisation of Citrate.Au. A: TEM of citrate stabilised gold nanoparticles, Citrate.Au. 




2.2 Europium (III) binding studies to peptides 
As peptides are useful vehicles in cellular delivery, it is interesting to investigate 
whether peptides are able to bind lanthanide ions for the development of luminescent 
peptide probes. The binding of lanthanide ions to ThioALNN peptide was investigated 
by luminescence spectroscopy. Upon titration of a stock solution of europium (III) into 
a solution of ThioALNN in water, an increase in europium emission is observed. 
Further additions of europium (III) resulted in a plateau indicative of the saturation of 
the peptide binding sites with europium (III). Since the ThioALNN peptide contains no 
chromophoric units for sensitisation of europium ion emission, any increase in 















emission intensity can be attributed to exclusion of water from the lanthanide 
coordination sphere due to a binding event. The luminescence spectra of the titration 
of a solution of europium (III) into a 0.18 mM solution of ThioALNN peptide shows an 
increase in europium emission upon addition of stock solution of europium (III) in 
water (figure 2.5). The europium (III) binding event to ThioALNN is shown by the 
saturation of europium emission at a europium (III) concentration of 60 µM. This 
suggests that the ratio of binding is three peptides to one lanthanide ion.  
 
 
Figure 2.5: Emission spectra and plot of emission intensity vs. concentration of Eu
3+
 of ThioALNN 
peptide upon the titration of Eu
3+
. Concentration of ThioALNN peptide in water = 0.18 mM.  
 
 
The addition of europium (III) to thioALNN can also be monitored by circular 
dichroism spectroscopy (CD). The addition of europium (III) induces a slight change 
in the CD spectrum, and monitoring the additions also gives an indication of the 
concentration at which the binding sites have become saturated (figure 2.6). 




















































in the CD spectrum, suggesting that the peptide structure has stabilised and the 
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Figure 2.6: Circular dichroism spectra of ThioALNN peptide, plus the addition of europium (III) ions. 








] = 72 µM () 
 
 
The longer peptide ThioKEESLADDL was also investigated as a potential lanthanide 
binding peptide. This peptide has been chosen for investigation as it carries a portion 
of the human NBS1 gene that interacts with ATM, a member of the 
phosphatidylinositol 3-kinase family. It is known to interfere with DNA repair 
mechanisms within cells. The peptide ThioKEESLADDL contains no chromophore 
unit similar to ThioALNN which could sensitise europium emission, therefore as with 
the ThioALNN peptide the emission observed is again attributed to the displacement 
of water molecules coordinated to the lanthanide ion. Titration of europium (III) ions 




europium from the increase in europium emission observed. The binding ratio of 
europium to ThioKEESLADDL was found to be 1:1 (figure 2.7).  
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Figure 2.7: Titration of Eu
3+
 into ThioKEESLADDL solution. [ThioKEESLADDL] = 0.18 mM. 
λexc = 280 nm. Left: Emission spectra of titration. Right: Plot of emission intensity increase vs. [Eu
3+
]. 





Circular dichroism shows a similar trend upon addition of europium (III) to a solution 
of ThioKEESLADDL peptide, with a change induced in the CD spectrum upon 
addition of europium (figure 2.8). This is potentially due a change in the structural 




















Figure 2.8: Circular dichroism of thioKEESLADDL peptide with the addition of europium (III). 
[ThioKEESLADDL] = 0.18 M (), [Eu
3+




The two peptides have different structures which can help to explain the different 
binding ratios of peptides to lanthanide ions. Lanthanide ions coordinate to hard 
bases, such as oxygen, therefore some of the groups on these peptides are suitable 
for lanthanide coordination. The carboxylates found within both of these peptide 
structures are the most likely to coordinate on these peptides. Comparing the 
numbers on these two peptides it can be seen that the ThioALNN peptide contains 
one carboxylic acid group whilst the ThioKEESLADDL peptide contains five. 
Therefore it is possible that one ThioKEESLADDL peptide can bind one lanthanide 
ion, as it is possible that the peptide is able to wrap around the lanthanide ion to form 
a complex. The ThioALNN peptide however is smaller with less available 
coordination sites, therefore it requires a higher number of peptides to efficiently 







2.3 Coating of gold nanoparticles with ThioALNN and ThioKEESLADDL 
  
Scheme 2.1: Schematic representation of ThioALNN.Au and ThioKEESLADDL.Au 
 
The coating of Citrate.Au with the peptides ThioALNN and ThioKEESLADDL was 
monitored by UV-Vis spectroscopy to observe any changes in the SPR band upon 
addition of the peptides. Citrate.Au was coated in ThioALNN peptide and the binding 
event was monitored by UV-Vis spectroscopy. The addition of ThioALNN peptide to 
Citrate.Au resulted in a 2 nm red-shift in SPR band (figure 2.9). This shift is in 
agreement with the shift observed in gold nanoparticles when stabilised with CALNN 
peptide.18 The nanoparticles were characterised by transmission electron microscopy 
(TEM) which confirmed the nanoparticles were uniform in shape with a diameter of 
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Figure 2.9: UV-Vis spectra and SPR shift plot of the titration of ThioALNN into Citrate.Au. 
[Citrate.Au] = 4.5 nM 
 
 
                    
Figure 2.10: TEM image of ThioALNN.Au. Scale bar = 20 nm 
 
 
Citrate.Au were coated with ThioKEESLADDL peptide using the same conditions as 
ThioALNN.Au. The shift in the SPR band was monitored by UV-Vis and found to be 





were also characterised by TEM, again showing nanoparticles uniform in shape 
between 10-15 nm in size (figure 2.12). There are however some slightly larger 

























































[ThioKEESLADDL] / M  
Figure 2.11: UV-Vis spectra and SPR shift plot of the titration of ThioKEESLADDL into Citrate.Au.  







Figure 2.12: TEM image of ThioKEESLADDL.Au. Scale bar = 20 nm. 
 
Studies of the size distribution of the gold nanoparticles were carried out using 
dynamic light scattering (DLS). The number distributions obtained by DLS (shown in 
table 2.1) for Citrate.Au, ThioALNN.Au and ThioKEESLADDL.Au agree with the 
size observed by TEM microscopy. The data recorded for ThioALNN also showed a 
small distribution at 1.2 ± 0.1 nm in both the number and intensity distribution. This is 
most likely an artefact which has caused the distributions to be slightly skewed. 
 
Sample Number Distribution Intensity Distribution 
Citrate.Au 13.7 ± 3.6 nm 30.0 ± 13.4 nm 
ThioALNN.Au * 1.2 ± 0.1 nm * 
17.0 ± 3.9 nm 
* 1.2 ± 0.1 nm * 
27.0 ± 8.6 nm 
ThioKEESLADDL.Au  10.7 ± 3.1 nm 31.3 ± 16.8 nm 






2.4 The binding of europium (III) to peptide coated nanoparticles 
2.4.1 The binding of europium (III) to ThioALNN.Au  
 
Scheme 2.2: Schematic representation of the preparation of Eu-ThioALNN.Au 
 
The lanthanide binding properties of the two peptides ThioALNN and 
ThioKEESLADDL have been confirmed by luminescence spectroscopy studies. To 
further study the lanthanide binding properties of these peptides, their ability to bind 
lanthanides whilst tethered to gold nanoparticles has also been investigated. 












                                       















Figure 2.13: UV-Vis spectra of Citrate.Au (), with the addition of ThioALNN [0.18 mM] in phosphate 
buffer (−−) and Eu
3+
 [0.52 mM] in water (). 
 
 
The binding of europium to ThioALNN.Au was monitored by luminescence 
spectroscopy upon titration of EuCl3.6H2O. Additions of europium (III) in µl aliquots 
into ThioALNN.Au lead to a strong increase in europium signal, which reaches a 
plateau indicative of saturation of peptide binding sites on the nanoparticle with 
europium (III). A small red-shift and a decrease in the intensity in the SPR band by 
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Figure 2.14: Luminescence spectra of ThioALNN.Au upon titration of Eu
3+
, [AuNP] = 4.5 nM, 





The Eu-ThioALNN.Au nanoparticles are less emissive than Eu-ThioALNN, which 
could possibly be due to quenching of the lanthanide luminescence due to close 
proximity to the gold surface.20 It is also possible that once bound to the gold surface, 
the peptide loses its structural freedom which may affect its ability to wrap around the 
lanthanide. This may cause the lanthanide ion to be exposed to water, which is 
known to quench the lanthanide emission signal. This possible explanation is 




7F1 in solutions of Eu-ThioALNN and Eu-ThioALNN.Au 
(figures 2.5 and 2.14), as the 5D0 → 
7F2 band is sensitive to the structural 
















Figure 2.15: UV-Vis spectra of the titration of Eu
3+
 into Citrate.Au (). [Citrate.Au] = 4.5 nM, 
[Eu
3+





     
In order to establish whether the increase in europium emission intensity can be 
attributed to the binding of the europium ions to the peptides, a control experiment of 
titrating europium (III) into Citrate.Au was carried out. This titration of europium (III) 
into Citrate.Au leads to immediate aggregation of the particles, which is shown by 
the growth of a UV-Vis band at 650 nm (figure 2.15). This demonstrates the ability of 
the ThioALNN peptide to stabilise gold nanoparticles, as the peptide coated 
nanoparticles do not aggregate upon addition of the same concentrations of 
europium (III).  Luminescence studies of this titration shows a very weak increase in 
europium signal upon titration of europium (III). This increase is significantly lower 
than that observed with the titration of europium (III) with the peptide coated gold 
nanoparticles, and was too weak to be corrected for residual europium emission 
therefore the emission increase found from this titration was not significant enough to 






                    
Figure 2.16: TEM image of Eu-ThioALNN.Au. Scale bar = 20 nm 
 
The Eu-ThioALNN.Au particles are similar in size to the ThioALNN.Au, with TEM 
showing them as approximately 13-15 nm (figure 2.16). The particle size would be 







2.4.2 The binding of europium (III) to ThioKEESLADDL.Au  
 
Scheme 2.3: Schematic representation of the preparation of Eu-ThioKEESLADDL.Au 
 
The binding of europium (III) to ThioKEESLADDL.Au was investigated in a similar 
way to ThioALNN.Au. The addition of europium (III) to ThioKEESLADDL.Au 
resulted in red-shift of the SPR band of 1 nm observed by UV-Vis spectroscopy 
(figure 2.17).  
 















Figure 2.17: UV-Vis spectra of Citrate.Au () with the addition of ThioKEESLADDL = 0.18 mM in 
phosphate buffer (−−) and Eu
3+












Luminescence studies of the titration of europium (III) into ThioKEESLADDL.Au 
showed an increase in europium emission with no point of saturation upon addition of 
europium (III). Titration of europium (III) into ThioKEESLADDL in solution shows a 
1:1 binding with a clear saturation point, which is indicative of complex formation. The 
peptide structure suggests that the peptide wraps around the lanthanide ion to form 
the complex. However in the case of the peptide immobilised on nanoparticles, the 
results imply that the peptide may have a different conformation making the binding 
of the lanthanide less strong. 
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Figure 2.18: Luminescence spectra of ThioKEESLADDL.Au upon titration of Eu
3+
 [AuNPs] = 4.5 nM, 









Figure 2.19: TEM image of Eu-ThioKEESLADDL.Au. Scale bar = 20 nm 
 
 
The TEM image of the Eu-ThioKEESLADDL.Au (figure 2.19) shows the particles to 
be in a similar size range to the Eu-ThioALNN.Au particles (figure 2.16). The 
nanoparticles appear to be disperse, however they are surrounded by other artefacts 
which are not as dense as the gold nanoparticles. This is most likely to be excess 
europium (III), which has dried onto the grid once the solvent has evaporated off. 
Studies of the peptide coated gold nanoparticles by circular dichroism show very 
weak signal for the samples (figure 2.20). Initial studies of ThioALNN.Au showed no 
change in the CD spectrum upon addition of the europium (III), nor any change from 
the Citrate.Au spectrum. The ThioKEESLADDL.Au spectrum however does show 
some variation from that Citrate.Au by CD spectroscopy. Whilst the overall CD signal 
is weak in comparison to the peptide in solution, there is a peak at approximately 
225 nm present in the ThioKEESLADDL.Au sample which is not present in the 




addition of europium into the ThioKEESLADDL.Au does not cause any significant 
changes to the CD spectrum. From the CD spectra of the ThioKEESLADDL in 
solution, any changes in the CD spectrum would be anticipated would be small. The 
gold nanoparticles are very strongly absorbing at lower wavelengths, particularly 
where the peptide signal would be anticipated. Therefore it is highly likely that the 
light is being absorbed by the nanoparticles, which gives rise to the weak signal 
observed.With the weak signal within the nanoparticle samples, it would be difficult to 
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Figure 2.20: Circular dichroism spectra of Citrate.Au (), ThioKEESLADDL.Au (−−−) and 
Eu-ThioKEESLADDL.Au (). [Citrate.Au] = 4.5 nM, [ThioKEESLADDL] = 0.18 mM, 
[Eu
3+




The peptides ThioALNN and ThioKEESLADDL have been found to bind lanthanide 




nanoparticles were prepared with the binding of europium (III) to the peptide coated 
nanoparticles, which was monitored by luminescence spectroscopy. The 
nanoparticles were characterised by absorption spectroscopy and TEM. The 
peptides used contain no chromophore for sensitisation of the bound europium (III), 
however there is great potential to improve the luminescent properties of peptide 






3.1 Synthesis of ThioALNN peptide 
 
 
ThioALNN was synthesised using a CEM discover SPS microwave reactor. FMOC-
Asn-(Trt)-Wang resin (0.208 g) was swollen in DMF (7 ml) for 15 minutes. The DMF 
was removed and the resin washed with DMF (5 x 7 ml). The FMOC protecting group 
of the amino acid was removed by adding 20 % piperidine in DMF (7 ml) and placing 
in the microwave reactor (Conditions: 20 W, 75 oC, 3 min). The deprotection solution 
was removed and the resin washed with DMF (5 x 7 ml). FMOC-L-Asn-(trt)-OH (0.5 
mmol) was added to the resin in DMF, along with the activator HBTU and the 
activator base DIEA and then coupled in the microwave reactor (Conditions: 20 W, 
75 oC, 3 min). The resin was then washed with DMF (5 x 7 ml). The deprotection and 
coupling was repeated for each of the amino acids, FMOC-L-Leu-OH (0.5 mmol), 
FMOC-L-Ala-OH.H2O (0.5 mmol) and thioctic acid (1 mmol). After the final coupling 
of the thioctic acid to the peptide, the resin was washed with DCM (5 x 7 ml). The 
peptide was cleaved from the resin in the microwave reactor (Conditions: 20 W, 35 
oC, 25 minutes) using a cleavage solution of 90 % TFA, 2 % anisole, 5 % thioanisole 
and 3 % EDT. The final solution was filtered, reduced in volume under N2 and cold 
diethyl ether (40 ml, -20 oC) was added which caused the formation of a white 




redissolved in water (40 ml) and acetic acid (15 ml) and freeze dried. The crude 
peptide was then purified by semi-prep HPLC (C18 column, Acetonitrile/Water/TFA). 
(5.2 mg, 8.4 %) MS (MALDI) m/z 641 [M+Na]+, 643 [M+2H+Na]+, 657[M+K]+, 659 
[M+2H+K]+. UV-vis (H2O) λmax 203 nm. 
 
The peptide ThioKEESLADDL was purchased from United Peptide Corporation, 
purified by HPLC, MS m/z 1206. The peptide was used without any further 
purification. 
 
3.2 Preparation of Citrate Stabilised Gold Nanoparticles, Citrate.Au 21 
All glassware were washed with aqua regia and dried prior to use. Hydrogen 
tetrachloroaurate (0.0672 g, 0.2 mmol) was dissolved in 200 ml water and heated 
under reflux. A solution of sodium citrate (0.228 g, 0.8 mmol) in water (20 ml) was 
added rapidly. The yellow solution became deep red in colour. The solution was left 
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Nanoparticles coated with lanthanide complexes and peptides for 
cellular imaging applications 
 
1 Introduction 
Lanthanide complexes are desirable probes for cellular imaging due to their unique 
photophysical properties. Their long luminescent lifetimes in the millisecond range 
and large Stoke shifts make them useful for avoiding detection of cell 
autofluorescence which is often observed.1 There have been many examples of 
lanthanide complexes developed for cellular imaging.2-4  Parker et al. have reported a 
range of luminescent lanthanide probes which have been found to localise within four 
sub-cellular regions; lysosomes, mitochondria, nucleus and a combination of 
mitochondria and lysosomes.4 They observed that the structure of the complex and 
the linkage of the chromophore to the lanthanide had an effect on the sub-cellular 
localisation of the complex.5-7 Bünzli et al. have reported bimetallic lanthanide 
helicates as probes for cellular imaging.8, 9 The helicates were found to be non-
cytotoxic and their uptake into cells was found to proceed by endocytosis, with 
localisation in the endoplasmic reticulum.  Europium helicates were successfully 
imaged by luminescence microscopy and confocal microscopy in HeLa cells 
(figure 3.1).9 Incubation of cells with various concentrations of the lanthanide 
helicates found that dosing with higher concentrations exhibited greater 
luminescence.9 The importance of concentration is evident from these studies, 
therefore tethering lanthanide complexes onto gold nanoparticles may provide an 








Figure 3.1: Structure of H2L used to form europium helicate Eu2(L)3 and luminescence and confocal 
microscopy of Eu2(L)3 incubated with HeLa cells. A: Merged bright-field and time-resolved 
luminescence microscopy of HeLa cells incubated with [Eu2(L)3]. Cells incubated with different 
concentrations of [Eu2(L)3] at 37 °C for 6 hours, λexc = 365 nm. B: Confocal microscopy images of 
HeLa cells incubated with different concentrations of [Eu2(L)3] during 18 h at 37 °C; λexc = 405 nm. 





Gold nanoparticles provide a suitable platform for the assembly of multiple probes. 
They are bio-inert and can be easily functionalised with moieties containing sulphur 
by the formation of sulphur-gold bonds. Gold nanoparticles have been reported to be 
functionalised with various molecules such as peptides,10-14 DNA,11, 15 fluorescent 
dyes16, 17 and lanthanide complexes.18-20 One of the first examples of lanthanide 
coated gold nanoparticles was the attachment of a surface-active europium DTPA 
bis-amide complex.18 Lanthanide coated gold nanoparticles have been used in 
cellular imaging and sensing applications. Lanthanide coated nanoparticles have 
been utilised to sense biologically relevant anions and molecules such as 
phosphates,21 proteins22 and enzymes.23 The transfection and genotoxicity of 









A: Luminescence Microscopy 




epithelial lung fibroblasts have been monitored by high resolution synchrotron X-ray 
fluorescence microscopy.20  
The combination of lanthanide complexes and peptides attached to gold 
nanoparticles has only recently been reported. The delivery of gold nanoparticles in 
platelets in a pH dependant manner was studied by co-coating gold nanoparticles 
with a europium complex and a pH low insertion peptide (pHLIP).19 In another 
approach, a peptide designed for multiple enzyme detection has been tethered to 
gold nanoparticles (figure 3.2).23 The peptide consists of a lanthanide complex on 
one end of the peptide and a coumarin on the other, with two sulphurs in the middle 
of the peptide to anchor the peptide to gold nanoparticles. The spacer between the 
lanthanide complex and the coumarin contains an amino acid sequence specific to 
two biologically relevant enzymes, matrix  metalloproteinase 2 and matrix 
metalloproteinase 7 (MMP-2 and MMP-7). Cleavage of the spacer between the two 
lumophores by the specific enzymes prevents fluorescence resonance energy 
transfer between the two lumophores and the gold nanoparticles causing an increase 
in emission. Gold nanoparticles coated with peptides and a FITC fluorophore have 
been used in a similar way for the detection of multiple proteinases.24 Protease 
specific peptides with attached lanthanides were tethered to Ru(bpy)3 doped silica 
nanoparticles for detection of multiple proteases by inductively coupled plasma mass 






Figure 3.2: Left: Schematic of gold nanoparticles functionalised with coumarin and a europium 
complex for detection of the enzymes MMP-2 and MMP-7.
23
 Right: Schematic of protease detection 
using silica nanoparticles and peptide/lanthanide complexes determined by ICP-MS.
25
 Diagrams 
reproduced from references 23 and 25 
 
 
Functionalisation of gold nanoparticles with peptides is of interest for the delivery of 
gold nanoparticles into cells. The addition of peptides onto nanoparticles allows for 
the specific targeting of certain organelles and the specific sub-cellular localisation of 
the nanoparticles within the cells. In this chapter, gold nanoparticles co-coated with 
lanthanide complexes and peptides for cellular imaging are reported. Photophysical 
studies of these lanthanide-peptide co-coated gold nanoparticles were carried out to 
investigate the effect of the binding of these two entities onto gold nanoparticles on 
the emissive properties of the lanthanide complex.  The particles have been 
characterised by UV-Vis and luminescence spectroscopy. The uptake of 
lanthanide/peptide gold nanoparticles into cells has been monitored by luminescence 





EuNapSAc complexes (figure 3.3). The previously reported europium complex 
EuSH,18 is a DTPA bis-amide complex with two thiophenol legs for lanthanide 
sensitisation and gold nanoparticle attachment. The EuQSH complex is a similar 
DTPA bis-amide complex with one thiophenol arm and one quinoline arm. Another 
europium complex used is EuNapSAc (supplied by Dr Stephen Hammond) which 
consists of a DTPA backbone for the chelation of the lanthanide ion, two naphthalene 
chromophores and two alkyl chains with terminal sulphurs for attachment to gold 
(figure 3.3). The sulphur atoms are protected with acetyl groups to prevent the 
formation of disulphide bonds.  
 
 
Figure 3.3: Structure of the europium complexes EuSH, EuQSH and EuNapSAc 
 
The peptides used in this chapter are based on known sequences which have been 
used for cellular targeting. Two of the sequences chosen, were based on known 
nuclear localisation sequences (NLS).10, 11, 13, 26 The third sequence is a peptide 




sequence that is known to interact with the enzyme ataxia telangiectasia mutated 



















2 Results and Discussion 
 
2.1 Synthesis of lanthanide complexes 
2.1.1 Synthesis of SH ligand and LnSH (Ln = Eu, Tb, Gd, Nd) complexes 
 
Scheme 3.1: Reaction scheme for the preparation of LnSH, where Ln = Eu, Tb, Gd and Nd. 
 
The SH ligand was synthesised by a condensation reaction in pyridine of 4-
aminothiophenol with DTPA-bis anhydride following a published procedure.18 The 
ligand was characterised by NMR and mass spectrometry. 
The LnSH (Ln = Tb, Nd, Gd) complexes were prepared by reacting the SH ligand 
with LnCl3.xH2O in degassed methanol. Acetonitrile was used to precipitate out the 
complex from the methanol, and the complex was isolated by filtration. EuSH was 
prepared by first preparing the potassium salt of the SH ligand by adding KOH into a 
solution of the SH ligand in methanol. Then EuCl3.6H2O was added to form the 
complex. The complexes were characterised by UV-Vis and mass spectrometry and 
the results showed agreement with the previous data reported.18, 28 
The UV-Vis spectra of the LnSH complexes in methanol showed a peak at 
approximately 266 nm, which is characteristic of the π-π* transition of the 










phenylamide group of the ligand. Luminescence studies of a solution of EuSH in 
methanol show the characteristic europium f-f transitions 5D0 → 
7FJ where J = 0, 1, 2, 
3, 4 at 580, 590, 614, 650 and 695 nm. The solution was excited at 270 nm, to 
correspond with the absorbance of the ligand. The excitation spectrum of the EuSH 
complex followed the profile of the UV-Vis spectrum of the ligand, which illustrates 
the energy transfer between the thiophenol groups of the ligand to the lanthanide. 
The emission spectrum of the TbSH complex and the NdSH complex was also 
recorded. A solution of TbSH complex dissolved in methanol showed the 
characteristic transition 5D4 → 
7FJ where J = 0, 1, 2, 3, 4, 5, 6 at 490, 546, 583, 620, 
649, 667, and 680 nm. The most intense transition was 5D4 → 
7F5 seen at 546 nm. 
The excitation spectrum of the TbSH solution was also recorded, with the profile 
matching that of the UV-Vis spectrum as with the EuSH complex. The emission 
spectrum of NdSH in methanol shows the typical transitions of neodymium 4F3/2 → 
4IJ 
where J = 9/2, 11/2 and 13/2. The phosphorescence signal of the GdSH complex 








2.1.2 Synthesis of QSH ligand and LnQSH (Ln = Eu, Gd, Nd) 
 
Scheme 2: Reaction scheme for the preparation of LnQSH 
 
The QSH ligand was synthesised by initially reacting 6-aminoquinoline with a 1:1 
molar ratio of DTPA bis-anhydride in pyridine, then 4-aminothiophenol is added to the 
reaction mixture. The reaction yields a combination of three different products; a 
DTPA ligand with two quinoline groups, a DTPA ligand with two thiophenol groups 
(SH ligand) and the desired product DTPA with one quinoline arm and one 
thiophenol arm (QSH ligand). Purification of the final product is achieved by 
preparative HPLC using a 0.05 % TFA, acetone/water gradient. A reducing agent, tris 
(2-carboxyethyl) phosphine hydrochloride (TCEP) was added to the crude product 
before purification by HPLC to reduce any disulphide bonds which could affect the 
purification. The final product was characterised by NMR and mass spectrometry.  
The complexes LnQSH (Ln = Eu, Gd, Nd) were prepared by adding LnCl3.nH2O to a 
solution of the QSH ligand. The pH was adjusted to 5 and the final complex was 
precipitated out of solution using acetonitrile. The complexes were characterised by 
mass spectrometry and elemental analysis. 










Photophysical studies of EuQSH were carried out and are shown in figure 3.5. The 
emission spectrum of the EuQSH complex in methanol shows the characteristic 
europium transitions 5D0 → 
7FJ where J = 0, 1, 2, 3, 4. The excitation spectrum of 
EuQSH shows a peak at 330 nm suggesting that the luminescence observed is 
caused by sensitisation of the lanthanide by the quinoline sensitiser. The 
luminescence lifetime recorded for this complex in methanol was found to be 0.78 
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Figure 3.5: Emission (), excitation () and UV-Vis (−−−) spectra of EuQSH complex in 
methanol. Emission λexc = 330 nm corrected for PMT response. Excitation λem = 614 nm. 
 
 
Studies of the luminescent properties of the NdQSH complex showed the 
characteristic emission profile attributed to the neodymium f-f transitions 4F3/2 → 
4IJ 
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Figure 3.6: Emission spectrum of NdQSH complex in methanol. λexc = 330 nm. 
 
 
The yttrium complex was prepared following the same procedure as the LnQSH 
complexes. The YQSH complex was characterised by mass spectrometry and 
1H NMR. The yttrium complex was prepared for analysis by 1H NMR spectrometry as 
it possesses similar coordination properties to the lanthanides, but does not cause 
peak broadening in NMR spectrum which is typically observed with the lanthanides. 
Comparison of the 1H NMR spectra of the QSH ligand and the YQSH complex shows 
some differences attributed to the complexation of the yttrium. The eight protons on 
the DTPA backbone appear in the NMR of the ligand as one singlet, but upon 
complexation the protons appear as two singlets each integrating for four protons. 
The aromatic protons of the quinoline and the thiophenol group exhibit some 
changes in the 1H NMR upon complexation, with the majority of peaks shifting 






2.2 Coating of gold nanoparticles with lanthanides complexes and peptides 
2.2.1 Lanthanide complexes on gold nanoparticles 
 
Figure 3.7: Schematic representation of EuS.Au, EuQS.Au and EuNapS.Au. 
 
The lanthanide complexes used within this chapter for the co-coating of Citrate.Au 
with lanthanide complexes and peptides are EuSH, EuQSH and EuNapSAc. The 






luminescent gold nanoparticles.18 The addition of the EuSH complex to gold 
nanoparticles results in 5 nm shift in the SPR band monitored by UV-Vis 
spectroscopy. Luminescence spectroscopy of EuS.Au shows the characteristic 
europium emission spectrum, with a luminescence lifetime similar to that of the 
europium complex in water. Coating Citrate.Au with EuQSH complex shows a 
similar trend, with a red-shift in the SPR band of 6 nm and the characteristic 
europium emission being observed. The luminescence lifetime recorded of EuQS.Au 
is similar to that of the complex in water, showing no quenching. Full characterisation 
of EuS.Au and EuQS.Au can be found in chapter 4. Another europium complex 
utilised for this work to prepare luminescent gold nanoparticles is EuNapSAc, 
prepared by Dr. Stephen Hammond. The addition of the EuNapSAc complex to gold 
nanoparticles causes a 5 nm red-shift in the SPR band. The luminescence lifetime of 




2.2.2 Coating of gold nanoparticles with peptides 
The surface coating of Citrate.Au with various peptides was monitored by UV-Vis 
spectroscopy to establish the overall shifts in the SPR band in the presence of the 
peptides, and to provide a comparison of the concentrations of peptide needed to 
obtain this shift. The two individual NLS peptides and the inhibitor peptide were used 
on their own to coat Citrate.Au, and also a combination of the NLS peptides and the 




CALNN sequence or a thioctic acid group to provide sulphurs for attachment to the 
gold nanoparticles.  
 
Peptide Sequence Molecular Weight Function 
Peptide 1 CALNNKKKKKKGGRGDMFGKEESLADDL 3081.58 NLS + Inhibition 
Peptide 2 ThioKKKKKKGGRGDMFGKEESLADDL 2754.32 NLS + Inhibition 
Peptide 3 CALNNGGFSTSLRARKAKEESLADDL 2767.09 NLS + Inhibition 
Peptide 4 ThioGGFSTSLRARKAKEESLADDL 2439.82 NLS + Inhibition 
Peptide 5 CALNNKKKKKKGGRGDMFG 2080.52 NLS 
Peptide 6 ThioKKKKKKGGRGDMFG 1753.25 NLS 
Peptide 7 CALNNKEESLADDL 1534.67 Inhibition 
Peptide 8 ThioKEESLADDL 1207.40 Inhibition 
Peptide 9 CALNNGGFSTSLRARKA 1766.02 NLS 
Peptide 10 ThioGGFSTSLRARKA 1438.75 NLS 
 
Table 3.1: Peptide sequences used for coating nanoparticles and their functions. The peptides are 
either functional nuclear localisation signals (NLS) or a peptide which inhibits ATM-mediated DNA 
damage response. The larger peptides 1-4 contain a combination of two different peptides. 
 
 
The peptides were all found to be soluble in phosphate buffer. Citrate.Au were 
coated with these peptides with the addition of µL aliquots of the peptide solution in 
buffer, monitoring the SPR band of the gold nanoparticles by UV-Vis spectroscopy. 
Titration of various peptides into Citrate.Au showed red-shifts in the SPR ranging 
from 2 - 4 nm (figure 3.8). Peptides 5 and 6 were found to cause severe aggregation 
of Citrate.Au at concentrations as low as 10 ηM and were also found to cause 
aggregation upon addition to partially coated EuNapS.Au which meant that they 
were not used in any further experiments. The aggregation observed upon the 
addition of these peptides is most likely to be caused by the six positively charged 






Figure 3.8: Titration of different peptides into Citrate.Au. Circled points show excess peptide leading 
to nanoparticle aggregation. [Citrate.Au] = 1.2 nM. A: ThioKKKKKKGGRGDMFGKEESLADDL 
(Peptide  2). B: ThioGGFSTSLRARKAKEESLADDL (Peptide 4). C: ThioKEESLADDL (Peptide 8). 
D: ThioGGFSTSLRARKA (Peptide 10) 
 
 
Comparing the SPR shifts of the thioctic-terminated peptides, a larger red-shift for the 
longer peptides (peptides 2 and 4) is observed, compared with peptides 8 and 10. 
Interestingly, even though peptide 6 causes aggregation of the Citrate.Au at very low 
concentrations, peptide 2 can be added to Citrate.Au and result in stable 




































































































0 5  1 0
- 8
1  1 0
- 7
1 .5  1 0
- 7
2  1 0
- 7
2 .5  1 0
- 7
3  1 0
- 7



























contains the same peptide sequence as peptide 6 except for an additional 
KEESLADDL sequence on the end of the peptide. This extra portion of peptide 
tethered onto the end seems to aid the stabilisation of Citrate.Au and prevent 
aggregation upon addition. This also appears to be the case with peptide 4 with the 
extra KEESLADDL portion, meaning that higher concentrations of approximately 
0.9 µM of peptide  can be added to the Citrate.Au causing no aggregation 
(figure 3.8B), compared with the smaller peptide 10 which can only be added to 
Citrate.Au at a concentration of 0.1 µM (figure 3.8D). Addition of an excess amount 
of the smaller peptides into gold nanoparticles appears to give rise to aggregation of 
the particles after the SPR band reaches a plateau, whilst the longer peptides are 
stable once the saturation point has been reached and do not exhibit a further shift in 
the SPR upon titration of excess peptide. From the titration of ThioKEESLADDL 
(peptide 8) into Citrate.Au it can be seen that a higher concentration of 45 µM of 
peptide can be added to the Citrate.Au compared with the two shorter NLS 
sequences (peptides 6 and 10) (figure 3.8C). The longer peptides give rise to a larger 
red-shift in the SPR peak of between 3-4 nm compared to the smaller peptides, 
which only lead to a 2 nm red-shift. This result is similar to the ThioALNN peptide 




2.3 Gold nanoparticles co-coated with lanthanide complexes and peptides 
Luminescent gold nanoparticles designed for cellular targeting and imaging were 




peptides. Co-coating of Citrate.Au was achieved by simply adding to the Citrate.Au 
a methanolic stock solution of lanthanide complex and a solution of peptide dissolved 
in a phosphate buffer (scheme 3.3). The lanthanide complexes were added taking 
into account the concentrations required to fully coat the Citrate.Au and the 
concentration required to give partial shift in the SPR band. The peptides used were 
a selection of the peptides shown in table 3.1. The binding of the lanthanide 







Scheme 3.3: Schematic representation of coating gold nanoparticles with a europium complex and 
peptide.  The first step involves the partial coating of gold nanoparticles by the titration of µL quantities 
of the europium complex in methanol. The second step is the titration of the peptide dissolved in 
phosphate buffer added in µL aliquots. 
 
 
The Citrate.Au nanoparticles were co-coated with the lanthanide complex and 
peptides by firstly adding small aliquots of a methanolic solution of the complex to 
EuQS.Peptide 3.Au 
Au 






give a partial shift in the SPR band. The peptides were then added and the resulting 
SPR shift was monitored by UV-Vis spectroscopy. Removal of any excess peptide or 
complex was carried out by passing the resulting solution through a Sephadex G25 
size exclusion column. Coated gold nanoparticles were then characterised by 
luminescence spectroscopy.  
 
 
2.3.1 Co-coating of gold nanoparticles with EuSH and peptides 
 The europium luminescence signal of the nanoparticles with different peptides and 
the EuSH complex show interesting results (figure 3.9). Even though the same 
concentration of EuSH complex was used to partially coat a 1.2 nM solution of 
Citrate.Au, the addition of the peptides leads to a decrease in the europium emission 
observed. All the solutions were isoabsorptive at the excitation wavelength, therefore 





















Figure 3.9: Luminescence spectra of EuS.Au (−  −  −), EuS.Peptide 2.Au (−−−), EuS.Peptide 4.Au 
(), EuS.Peptide 10.Au (). λexc = 270 nm. The nanopartcles were prepared by mixing 
[EuSH] = 4.5 µM. [AuNPs] = 1.2 nM. [Peptide 2] =1.6 µM. [Peptide 4] =6.8 µM. [Peptide 10] = 52 nM 
 
 
The emission spectra of the partially coated EuS.Au shows greater luminescence 
than the particles that have additional peptide on the surface. The most dramatic 
decrease in europium luminescence signal is with EuS.Peptide 4.Au, with a 70 % 
decrease compared with EuS.Au. EuS.Peptide 4.Au shows a greater decrease in 
europium emission compared to EuS.Peptide 2.Au and EuS.Peptide 10.Au. The 
luminescence signal for EuS.Peptide 2.Au and EuS.Peptide 10.Au are similar with 
a 9 % and 28 % decrease respectively from the europium signal observed from 
EuS.Au suggesting that the presence of these peptides has a similar effect on the 
emissive properties of the complex. Peptide 10 and peptide 4 are similar peptide 
sequences, with peptide 4 having a longer amino acid sequence. However the 
concentrations of these peptides added to coat the gold nanoparticles is significantly 




peptide added to coat the particles, the more that the peptide has an effect on the 
emission of the complex.  
 
 
2.3.2 Co-coating of gold nanoparticles with EuNapSAc and Peptides 
A similar examination of the effect of the peptide on the europium signal of 
EuNapSAc coated nanoparticles shows little effect (figure 3.10). Any apparent 
increase in the emission can be attributed to an increase in the baseline of the 
emission spectra. The different effect on the emissive properties of the two different 
complexes is likely to be due to the different heights of the two complexes, as the 
EuNapSAc complexes has long alkyl chains to hold the lanthanide ion away from the 
nanoparticle surface. 
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Figure 3.10: Luminescence spectra of partially coated EuNapS.Au (−  −  −), 
EuNapS.Peptide 2.Au (−−−), EuNapS.Peptide 4.Au (), and EuNapS.Peptide 10.Au (). 
λexc = 310 nm. The nanoparticles were prepared by mixing [EuNapSAc] = 1 µM. [Citrate.Au] = 1.3nM, 






The europium complexes predominately studied with peptides for cellular microscopy 
were EuQSH and EuNapSAc as they can be excited at wavelengths greater than 
310 nm which is more desirable for the optics found in the microscope.  
Examination of the EuNapS.Au with two of the CALNN terminated peptides shows a 
different trend than previously observed with the thioctic terminated peptides. 
Preparation of EuNapS.Peptide 1.Au was achieved by firstly the titration of µL 
aliquots of EuNapSAc dissolved in methanol to Citrate.Au give a red-shift in the SPR 
band of 3 nm. A further 1 nm red-shift is observed upon addition of the 
CALNNKKKKKKGGRGDMFGKEESLADDL (peptide 1) (figure 3.11). This suggests 
that both the europium complex and the peptide are bound to the surface of the gold 
nanoparticles. The addition of a further excess of complex causes little change in the 
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Figure 3.11: UV-Vis and emission spectrum of EuNapSAc CALNNKKKKKKGGRGDMFGKEESLADDL 
(peptide 1) gold nanoparticles EuNapS.Peptide1.Au. UV-Vis (left) Citrate.Au (−−−−) with the addition 
of 9.4 µM EuNapSAc () and 0.03 µM peptide 1 (). A further addition of 44 µM EuNapSAc was 




remove excess complex and peptide by size exclusion chromatography. Emission spectrum corrected 
for PMT response. 
 
 
Comparison of the EuNapSAc complex with different peptides shows an interesting 
result. The addition of the peptides cause a decrease in the emission of the europium 
compared with EuNapS.Au (figure 3.12). Peptide 1 causes a significant decrease in 
the europium emission, with the emission being reduced to a third of that observed 
with EuNapS.Au. However, the addition of CALNNGGFSTSLRARKAKEESLADDL 
(peptide 3) causes very little difference in the europium emission signal compared 
with EuNapS.Au.  
The luminescence lifetimes show that the EuNapSAc complex has a higher lifetime 
of 720 µs in water than on gold nanoparticles which was found to be 590 µs. The 
presence of the peptide 1 with the EuNapSAc complex causes a decrease in the 
luminescence lifetime both in water and on gold nanoparticles with lifetimes of 640 µs 
and 530 µs respectively (table 3.2). The recorded lifetime of 630 µs for 
EuNapS.peptide 3.Au is higher than the lifetime of 590 µs for EuNapS.Au. The 
emission intensity of EuNapS.peptide 3.Au is similar to that of the EuNapS.Au, 
which suggests that the peptide does not greatly affect the emissive properties of the 
europium complex on nanoparticles. Peptide 1 contains a section of positively 
charged lysine residues which may be a contributing factor to the poor emission 











EuNapS.Au 590 µs 0.99779 
EuNapSAc in water 720 µs 0.99946 
EuNapS.Peptide 1.Au 530 µs 0.99401 
EuNapSAc Peptide 1 in 
water 
640 µs 0.99933 
EuNapS.Peptide 3.Au 630 µs 0.9897 
EuNapSAc Peptide 3 in 
water 
700 µs 0.99944 
 
Table 3.2: Comparison of luminescence lifetime of the EuNapSAc complex with peptides in water and 
on gold nanoparticles. 
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Figure 3.12: Comparison of emission spectra of EuNapS.Au (), EuNapS.Peptide 1.Au (− − −) 
and EuNapS.Peptide 3.Au (). λexc = 310 nm. The nanopartcles were prepared by mixing 
[Citrate.Au] = 9.3 nM, [EuNapSAc] = 9.5 µM, [Peptide 1] = 34 nM, [Peptide 3] = 1.2 µM. 
 
 
Comparing the luminescence spectra of the luminescent nanoparticles 
EuNapS.Peptide 1.Au, EuNapS.Peptide 2.Au, EuNapS.Peptide 3.Au and 
EuNapS.Peptide 4.Au shows an interesting result. The europium emission from the 




in comparison with the EuNapS.Au containing the same concentration of EuNapSAc. 
However EuNapS.Peptide 1.Au shows a significant decrease in emission compared 
with EuNapS.Au. The main difference between peptide 1 and 2 is the surface 
attachment, with peptide 1 having a terminal CALNN group and peptide 2 having a 
thioctic acid group. This makes the overall length of peptides different which 
potentially means that different amino acids at different distances from the gold 
surface compared with the EuNapSAc complex. The potential problem with this 
peptide is the group of positively charged lysines which may interact unfavourably 
with the europium complex. The different terminal surface attachment group may 
cause these charged groups to be at different heights from the nanoparticle surface. 




2.3.3 Co-coating gold nanoparticles with EuQSH and Peptides 
The effect of peptides 1-4 has also been investigated on the EuQSH complex. 
Comparing the luminescence spectra of EuQS.Peptide 1.Au, EuQS.Peptide 2.Au, 
EuQS.Peptide 3.Au and EuQS.Peptide 4.Au shows the presence of the different 
peptides has different effects on the luminescence (figure 3.13). It is clear from the 
luminescence spectra that the europium emission signal is considerably reduced in 
the presence of peptide 1, with four-fold increased emission signal observed for 
EuQS.peptide 2.Au and EuQS.peptide 4.Au and an eight-fold increase observed 
with EuQS.peptide 10.Au. This is similar to the trend shown with the EuNapSAc 




emission whilst EuQS.Peptide 4.Au has a two-fold greater emission intensity in 
comparison. Overall from the luminescence spectra of these nanoparticle samples, it 
can be seen that the trends are very similar for the EuQSH complex and the 
EuNapSAc complex in the presence of these peptides.  
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Figure 3.13: Luminescence spectra of EuQS.Peptide 1.Au (), EuQS.Peptide 2.Au (- - - -), 
EuQS.Peptide 3.Au (-  -  -) and EuQS.Peptide 4.Au (). λexc = 330 nm. The nanopartcles were 
prepared by mixing [Citrate.Au] = 9.3 nM, [EuQSH] = 53 µM, [Peptide 1] = 38 nM, 




2.4 Preparation and characterisation of europium and peptide coated 
platinum nanoparticles 
Platinum nanoparticles were also investigated as a potential scaffolds for lanthanide 
complexes and peptides. Unlike gold nanoparticles, platinum nanoparticles do not 
possess a surface plasmon resonance that can be monitored to determine the 
coating. An advantage of this however is that the platinum nanoparticles are not as 




photophysical properties of the lanthanide on the surface. Citrate stabilised platinum 
nanoparticles, Citrate.Pt, were prepared by the citrate reduction of chloroplatinic acid 
hexahydrate under reflux. The particles produced were spherical and approximately 
6 nm in diameter. Platinum nanoparticles can be coated in a similar way to 
Citrate.Au, utilising functionalising moieties containing sulphur groups. Platinum 
nanoparticles however do not possess a surface plasmon resonance that can be 
monitored by UV-Vis spectroscopy, therefore this technique cannot be used to 
monitor the surface coating. The EuNapSAc complex was used to coat Citrate.Pt, 
with peptides 1 and 3. The prepared platinum nanoparticles were characterised by 
TEM and luminescence spectroscopy (figure 3.14). 
 
  
Figure 3.14: TEM image of EuNapS.Peptide 3.Pt. Scale bar = 20 nm 
 
 
Luminescence studies of the EuNapSAc complex with platinum nanoparticles show 




emission intensity, suggesting that the platinum nanoparticles do not affect the 
emissive properties of the complex. The addition of peptide 3 causes a dramatic 
increase in the europium emission, with the emission intensity doubling with the 
presence of peptide 3. Peptide 1 has the opposite effect, with its addition to 
EuNapSAc coated platinum nanoparticles causing the europium emission to 
decrease. The trend in the emissive properties of EuNapSAc complex in the 
presence of peptide 1 and peptide 3 is similar in both gold and platinum 
nanoparticles. 
 














 / nm  
Figure 3.15: Emission spectra of EuNapS.Pt (), EuNapSAc in water (         ) EuNapS.peptide 1.Pt 
() and EuNapS.peptide 3.Pt (−−−). λexc = 310 nm. The nanoparticles were prepared by mixing 









EuNapS.Pt 580 µs 0.99677 
EuNapSAc in water 720 µs 0.99946 
EuNapS.Peptide 1.Pt 540 µs 0.99455 
EuNapSAc Peptide 1 in 
water 
640 µs 0.99933 
EuNapS.Peptide 3.Pt 820 µs 0.99799 
EuNapSAc Peptide 3 in 
water 
700 µs 0.99944 
 
Table 3.3: Comparison of luminescence lifetime of the EuNapSAc complex with peptides in water and 
on platinum nanoparticles. 
 
 
Studies of the luminescence lifetime of the platinum nanoparticles show a similar 
trend to that of the co-coated gold nanoparticles. The lifetime of 820 µs recorded for 
EuNapS.Peptide 3.Pt is significantly higher than the complex on platinum 
nanoparticles, EuNapS.Pt, with a lifetime of 580 µs. It is also higher than EuNapSAc 
in water and EuNapSAc with peptide 3 in water, with lifetimes of 720 µs and 700 µs 
respectively. As with the gold nanoparticles, EuNapS.Peptide 1.Pt has a lower 
lifetime of 540 µs compared with EuNapS.Pt. 
 
 
2.5 Cellular imaging with lanthanide and peptide coated gold and platinum 
nanoparticles  
Citrate.Au were coated in EuNapSAc complex and peptides for dosing cancer cells 
for luminescence imaging. The cell line dosed with gold nanoparticles was the A549 
cell line, which is a human adenocarcinoma alveolar basal epithelial cell line. Cells 




fluorescence caused by the cell media, as cell media containing phenol red is likely 
to give rise to some fluorescence which could lead to false positive results when 
trying to detect luminescence from the cells incubated with the lanthanide coated 
nanoparticles. The cells were then incubated for 24 hours with the gold nanoparticles 
and fixed with 100 % methanol at -20 oC. Figure 3.16 shows the bright field and 
fluorescence images of A549 cells incubated with EuNapS.peptide 1.Au. There is 
luminescence observed from the cells imaged, suggesting some uptake of 
nanoparticles into the cells. A steady state emission spectrum was recorded from the 
cell sample and the emission recorded from the cells was attributed to europium. 
Similar luminescence was observed upon incubation of A549 cells with 




Figure 3.16: EuNapS.Peptide 1.Au, A549 cells. Left: Bright-field image, Right: Luminescence imaging 
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Figure 3.18: Emission spectrum from luminescence microscopy of EuNapS.peptide 1.Au in A549 
cells. λexc = 330 nm. *scattering peak 
 
 
Figure 3.17: EuNapS.Peptide 3.Au, A549 cells. Left: Bright-field image, Right: Luminescence imaging 



















 /nm  
Figure 3.19: Emission spectrum from luminescence microscopy of EuNapS.peptide 3.Au in A549 
cells. λexc = 330 nm. *scattering peak 
 
 
Luminescence microscopy was also carried out with gold nanoparticles coated with a 
combination of EuQSH and peptides 1-4. However there was no luminescence 
observed with these nanoparticles. The EuQSH peptide nanoparticles also exhibited 
weaker emission in solution than the EuNapSAc peptide nanoparticles which may 
explain why they could not be observed in cells. Figure 3.20 shows A549 cells dosed 
with EuQS.peptide 3.Au. The cells are clearly visible in the bright field image, but 









Citrate.Pt were also coated in the EuNapSAc complex and peptides 1 and 3. 
EuNapS.Peptide 1.Pt and EuNapS.Peptide 3.Pt were incubated with A549 cells for 
luminescence imaging. From the images in figure 3.21, it can be seen that the cells 
exhibit some luminescence for cellular imaging, but the luminescence was very weak 
compared with EuNapS.Peptide 1.Au and EuNapS.Peptide 3.Au. 
 
Figure 3.20: EuQS.Peptide 3.Au, A549 cells. Left: Bright-field image, Right: Luminescence image 








Gold and platinum nanoparticles coated with europium complexes and peptides have 
been prepared and characterised by UV-Vis and luminescence spectroscopy. The 
different structures of the peptides have different effects on the emissive properties of 
the lanthanide complexes on gold nanoparticles. On comparison of the longer 
peptides, peptide 3 shows the least effect on the luminescent properties of the 
lanthanide complexes and peptide 1 showing the most pronounced effect. The 
highest europium luminescence was observed with the EuNapSAc complex in the 
presence of the peptides on gold nanoparticles. To investigate these lanthanide and 
peptide coated nanoparticles as lanthanide imaging probes, selected nanoparticles 
were incubated with cells. Luminescence microscopy images showed europium 
luminescence with the cells incubated with EuNapS.Peptide1.Au, 
EuNapS.Peptide 3.Au, EuNapS.Peptide 1.Pt and EuNapS.Peptide 3.Pt. This 
Figure 3.21: EuNapS.Peptide 3.Pt, A549 cells. Left: Bright-field image, Right: Luminescence image 





suggests that the EuNapSAc complex is a good luminescent probe for cellular 
imaging. Whilst these nanoparticles show promise as imaging probes in cells, further 
investigation could be carried out into designing lanthanide complexes that are 
unaffected by the presence of the peptide on the gold nanoparticle surface, The 
lanthanide complex would have to include a strongly chelating component to ensure 
the lanthanide remains firmly bound, and would also require sulphur(s) for binding to 
the gold nanoparticles. The ratio of peptide and lanthanide complex could also be 
examined further to investigate the highest ratio of lanthanide complexes that can be 
added, whilst still having enough peptide to transport the nanoparticles into cells. 
These are all factors which could be investigated in order to improve the potential of 











Acetic anhydride (220 ml, 2.33 mol) was added slowly via a dropping funnel to a 
stirring suspension of H5DTPA (160.6 g, 0.41 mol) in pyridine (150 ml) at 65
oC. The 
solution was stirred for 5 h and the solid was isolated by suction filtration and washed 
with acetic anhydride (2 x 50 ml). Acetonitrile (250 ml) was added to the solid and the 
solution refluxed for 1 h. Once the solution had cooled, the white solid was isolated 
by suction filtration and washed with acetonitrile (2 x 50 ml) and diethyl ether 
(2 x 50 ml). The final solid was dried in vacuo. (134.69 g, 92 %) 1H NMR (300 MHz, 
D2O) δ (ppm) 3.98 (8H, s, NCH2CO), 3.63 (2H, s, NCH2COOH), 3.48 (4H, t, 
NCH2CH2N), 3.18 (4H, t, NCH2CH2N).  
 
 
3.2 Preparation of 1,11-(bis(4amidothiophenol)-1,11-dioxo-3,6,9-triaza-3,6,9-






4-aminothiophenol (2. g, 16 mmol) was added to a solution of DTPA bis-anhydride 
(1.02 g, 2.8 mmol) in pyridine (10 ml) and stirred under nitrogen for 24 h. The 
resulting cloudy yellow solution was filtered, and the pyridine removed to give a thick 
yellow oil. Water (8 ml) was added to the oil and the crude ligand was isolated by 
lowering the pH to 3 using conc. HCl. The water was decanted from the flask, and 
the remaining solid was washed with water (2 x 20 ml) and acetonitrile (2 x 20 ml) 
and stirred in acetonitrile (50 ml) until a pale yellow powder is formed. The precipitate 
was isolated by suction filtration, and washed with acetonitrile (2 x 10 ml) and diethyl 
ether (2 x 20 ml). 
Hydrazine monohydrate (3 ml) was added dropwise to a solution of crude product in 
pyridine (20 ml). The pyridine was then removed by rotary evaporation and the 
product was redissolved in water and filtered. The solution was acidified to pH 3 with 
the addition of conc. HCl. The bottom layer was isolated and washed with acetonitrile 
(2 x 25 ml), then stirred in acetonitrile (2 x 50 ml) until an off white precipitate had 
formed. The powder was collected by filtration and washed with acetonitrile 
(2 x 10 ml) and diethyl ether (2 x 20 ml) and then dried in vacuo. (0.34 g, 40 %) 
1H NMR (300 MHz, MeOD-D4) δ (ppm) 7.41 (4H, d, ArH), 7.15 (4H, d, ArH),  
4.10 (2H, s, central - CH2COOH), 3.62 (4H, s CH2COOH), 3.59 (4H, s, -CH2CONH), 
3.50 (4H, t, NCH2CH2N), 3.23 (4H, t, NCH2CH2N). 
13C NMR (400 MHz, MeOD-D4) 
174.6 (2xC, CH2COOH), 171.5 (1xC, CH2COOH), 136.9 (2xC, ArC), 130.8 (4xC, 
ArC), 127.8 (2xC, ArC), 122.2 (4xC, ArC), 59.1 (2xC, CH2CO), 56.3 (2xC, 
NCH2COOH), 55.2 (2xC, central- NCH2COOH), 55.0 (2xC, NCH2CH2N), 51.1 (2xC, 
NCH2CH2N). MS (ES





3.3 Preparation of LnSH (Ln = Tb, Nd, Gd and Eu)28 
LnSH: SH ligand (0.2 g, 0.3 mmol) was added to a solution of LnCl3.xH2O (0.3 mmol) 
in degassed methanol (3 ml) and the solution was sonicated until the ligand had 
completely dissolved. Acetonitrile (20 ml) was added to the solution which caused the 
complex to precipitate out. The precipitate was collected under nitrogen and washed 
with acetonitrile (2 x 10 ml) and diethyl ether (2 x 10 ml). The final complex was dried 
in vacuo. 
 
TbSH: Yield 97 %, MS (ES+) m/z 786.3 [M+Na]+, UV-Vis (MeOH), λmax nm (log ε): 
266 nm (4.4) 
 
NdSH: Yield 84 %, MS (ES+) m/z 749.4 [M+H]+, UV-Vis (MeOH), λmax nm (log ε): 
267 nm (4.4) 
 
GdSH: Yield 92 %, MS (ES+) m/z 784 [M+Na]+, UV-Vis (MeOH), λmax (log ε): 267 nm 
(4.3) 
 
EuSH: SH ligand (0.036 g, 0.06 mmol) was dissolved in degassed methanol (1 ml). A 
solution of KOH (0.0105 g, 0.18 mmol) in degassed methanol was added to the H3L
1 
solution and stirred for 12 h. The solvent was removed to give the white potassium 
salt of the SH ligand, which was re-dissolved in degassed water (1 ml). EuCl3.6H2O 
(0.0218 g, 0.08 mmol) was added to the solution, which caused the formation of a 




acetone (2 x 5 ml) and diethyl ether (2 x 5 ml). The final solid was dried in vacuo. 
Yield 53 %, UV-Vis (MeOH), λmax (log ε): 266 nm (4.2).  
 
 
3.4 Preparation of 1-(6-amidoquinoline), 11-(4-amidothophenol)-1,11-dioxo-




DTPA bisanhydride (2.45 g, 7 mmol) was stirred in pyridine (100 ml). 6-
aminoquinoline (0.99 g, 7 mmol) was added to the solution and stirred at room 
temperature under nitrogen for 45 minutes. 4-aminothiophenol (0.87 g, 7 mmol) was 
added to the reaction mixture and stirred for 2 hours at room temperature under 
nitrogen. Water (80 ml) was added and stirred for 30 minutes. Solvent was removed 
in vacuo to give a yellow solid. The solid was dissolved in degassed water, and the 
pH was reduced to pH 3 with conc. HCl under nitrogen which caused the formation of 
a yellow precipitate. The water was decanted off and the precitipate was washed with 
50 ml degassed water and 50 ml degassed acetonitrile. The precipitate was stirred in 




under nitrogen and washed with degassed acetonitrile (2 x 25 ml) and diethyl ether 
(2 x 25 ml) to yield a bright yellow solid. (0.893 g, 21 %).  
This crude product was purified by prep HPLC (C12 column, Acetone/Water/0.05 % 
TFA). Briefly, the crude product was dissolved in 1:1 THF: water, with tris 
(2-carboxyethyl) phosphine hydrochloride (TCEP) added in excess to reduce any 
disulphide bonds. The sample injection size was 100 mg/ml. (0.157 g, 17.5 %)  
1H NMR (300 MHz, D2O) δ (ppm)  8.46 (1H, d, ArH), 8.00 (1H, d, ArH), 7.74 (2H, d, 
ArH), 7.51 (1H, dd, ArH), 7.23 (1H, q, ArH), 6.02 (2H, d, ArH), 6.68 (2H, d, ArH), 




3.5 Preparation of LnQSH (Ln = Eu, Nd and Gd) 
LnQSH: LnCl3.xH2O (0.06 mmol) was added to a solution of the QSH ligand 
(0.06 mmol) in 5 ml water and stirred under nitrogen. The pH was adjusted to 5 with 
the dropwise addition of tetrabutylammonium hydroxide (40 % w/w). The volume of 
the solution was reduced to 1 ml in vacuo. Degassed acetonitrile (30 ml) was added 
to precipitate LnQSH. The precipitate was collected by suction filtration under 
nitrogen and washed with acetonitrile (5 ml) and diethyl ether (5 ml). The final solid 
was dried on a high vacuum line.  
 
EuQSH: Yield = 91 % MS (ES
+) m/z 777 [M+H]+; CHN analysis: Anal. Calc. for 





NdQSH: Yield = 58 % CHN analysis: Anal. Calc. for C29H31N6O8SNd C: 45.48; 
N: 10.98; H: 4.08. Found C: 45.29; N: 10.91; H: 4.16  
 
GdQSH: Yield = 76 % CHN analysis: Anal. Calc. for C29H31N6O8SGd(H2O)3 C: 41.67; 
N: 10.06; H: 4.47. Found C: 41.60; N: 10.01; H: 4.05 
 
YQSH: Yield = 88 % MS (ES-) m/z 711 [M-H]- 1H NMR (300 MHz, MeOD) δ (ppm)  
8.46 (1H, s, ArH), 8.15 (1H, s, ArH), 8.00 (1H, d, ArH), 7.64 (2H, q, ArH), 7.21 (1H, 
m, ArH), 7.02 (2H, d, ArH), 6.08 (2H, d, ArH), 2.96 (4H, s, NCH2COOH), 2.91 (2H, s, 




3.6 Preparation of citrate stabilised platinum nanoparticles (Citrate.Pt) 
All glassware was washed with Aqua Regia and dried prior to use. Chloroplatinic acid 
hexahydrate (9.3 mg, 17.9 mmol) was dissolved in 150 ml water and heated under 
reflux. A solution of sodium citrate (18 mg, 61.2 mmol) in water (18 ml) was added 
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The self-assembly of multiple probes onto gold surfaces is particularly desirable for 
use as sensors and multimodal imaging agents. Probes with a variety of functions 
can be assembled onto the same nanoparticle to give the nanoparticle multimodal 
properties,1 or work as sensors for the detection of multiple analytes and biological 
molecules in solutions containing complex mixtures of molecules.2 The assembly of 
probes on surfaces can also facilitate energy transfer between donor and acceptor 
molecules. There have been many examples of gold nanoparticle functionalised with 
donor and acceptor molecules designed for Förster resonance energy transfer 
(FRET). FRET systems are often utilised for sensing biologically relevant analytes, 
metal ions, proteins and enzymes. Gold nanoparticles have been widely researched 
in this field as they are able to act as fluorescence quenchers. Fluorophores have 
been attached to gold nanoparticles, which induces fluorescence quenching by FRET 
between the fluorophore and the gold nanoparticles. The fluorophore acridine orange 
has been non-covalently absorbed onto gold nanoparticles which induce 
fluorescence quenching in close proximity to the surface (figure 4.1A). These 
nanoparticles can be used in the sensing of biological thiols, as thiols are able to 
displace the fluorophore from the nanoparticle causing an increase in fluorescence 
observed.3 Release of the fluorophore from the gold nanoparticle surface reduces the 
FRET between the fluorophore and the gold nanoparticles and causes the 




hydrogen peroxide, glucose and uric acid using gold nanoparticles conjugated with 
an enzyme horseradish peroxidase.4 Hydrogen peroxide is able to catalyse the 
binding of a tyramide moiety labelled with tetramethyl rhodamine to the enzyme 
horseradish peroxidase (HRP) or bovine serum albumin (BSA) (figure 4.1B and C). 
The binding of the labelled tyramide to the enzyme conjugated to gold nanoparticles 
causes the fluorescence of the rhodamine to be quenched. Thus the presence of 
hydrogen peroxide can be detected by the decrease in fluorescence observed from 
the rhodamine once it is bound to HRP or BSA.  
 
 
Figure 4.1: Schematic representations of two different FRET systems using gold nanoparticles 
(A and B). A: Acridine orange labelled gold nanoparticles for the sensing of biothiols.
3
 B: BSA and 
HRP coated gold nanoparticles with tyramide labelled TMR for the detections of hydrogen peroxide. 
C: Reaction scheme of the enzymatic reaction for the detection of hydrogen peroxide.
4
 Figures 







Scheme B: Sensing for hydrogen peroxide using a BSA 
and HRP coated gold nanoparticles and tyramide 
labelled TMR FRET system 
Scheme C: Reaction scheme of the enzymatic reaction 
of hydrogen peroxide with BSA and HRP – AuNP and 
tyramide labelled TMR 
Scheme A: Sensing for biothiols with Acridine Orange-




The development of multimodal gold nanoparticles has recently become of interest to 
many researchers. The ease of modification and large surface area of gold 
nanoparticles gives great potential for the attachment of several different 
functionalising moieties to the same nanoparticle. This allows for the development of 
probes that can be used for multiple imaging applications5-7 as well as drug delivery8 
and therapeutics.9  One example of this is the gadolinium-enriched DNA coated gold 
nanoparticles Cy3-DNA-Gd@AuNP developed by Meade et al.7 The nanoparticle 
conjugates contain gadolinium for use as an MRI contrast agent, and also the 
fluorescent dye Cy3 to allow the uptake of the nanoparticles to be monitored by 
fluorescence microscopy (figure 4.2). 
 
 
Figure 4.2: Development and characterisation of DNA-Gd@AuNP.
7
 A: Synthesis scheme of 
Cy3-DNA-Gd@AuNP. B: T1-weighted MR image of NIH/3T3 cells incubated with 20 mM and 5.0 mM 
(Gd
III 
concentrations) Cy3-DNA-Gd@AuNP and DOTA-Gd
III 
for 24 h at 14.1 T (600 MHz) and 25 oC. 
C: Confocal fluorescence micrograph of NIH/3T3 cells incubated with 0.2 nM particle concentration 
of Cy3-DNA–Gd@AuNPs for 4.0 h and a 24 h leach in fresh media and 1 mM DAPI (4’,6-diamidino-
2-phenylindole) for 10 min. Image shows merge of the blue (DAPI) and red (Cy3-DNA-Gd@AuNPs) 











Gadolinium DOTA complexes are attached using click chemistry onto a 
thiol-containing poly-dT DNA oligomer for attachment to citrate-stabilised gold 
nanoparticles. Upon incubation of NIH/3T3 cells with 20 µM Cy3-DNA-Gd@AuNP, 
the conjugate was found to give a 43 % reduction in T1 compared with the free 
Gd-DOTA complex at the same concentration. Fluorescence imaging shows the 
accumulation of these particles in cells after 4 hours incubation, which shows that the 
Cy3-DNA-Gd@AuNP conjugates are a versatile multimodal imaging agent 
(figure 4.2C). Gold nanoparticles are also known to be a suitable contrast agent for 
computed tomography (CT), which the authors suggest make these 
Cy3-DNA-Gd@AuNP conjugates suitable for CT as well as fluorescence and MRI. 
With emission in the visible and near-infrared regions and long luminescence 
lifetimes, lanthanides can be used as imaging agents using a variety of techniques. 
The paramagnetic properties of gadolinium also make it widely used as an MRI 
contrast agent. By combining different lanthanides into a single probe, it is possible 
that the different photophysical or paramagnetic properties can be exploited allowing 
different techniques to be used in their detection.10  
Lanthanides have been previously found to exhibit energy transfer between two 
different lanthanide DTPA-bis amide complexes in solution upon the formation of 
macrocycles by disulphide bonds.11 The macrocycles exhibit weak energy transfer 
between the lanthanide ions when the two complexes are assembled into 
macrocycles but as yet this energy transfer phenomenon has not been reported on 




Typically lanthanide complexes are designed with the inclusion of a chromophore for 
the sensitisation of lanthanide ions, as lanthanide ions are typically poor absorbers. 
However some examples of the self-assembly of lanthanide complexes with a 
chromophore on gold nanoparticles have been reported. The addition of a diketonate 
to gold nanoparticles coated in a macrocyclic europium complex causes a ‘switch on’ 
effect in the lanthanide luminescence (figure 4.3A).12 The diketonate acts a 
sensitising unit for the lanthanide, as the macrocycle contains no chromophore. The 
pH dependent self-assembly of the diketonate with the europium complex allows 
energy transfer from the diketonate to the europium ion to produce luminescent gold 
nanoparticles. This principle has also been applied to the sensitisation of near-
infrared lanthanides with xylenol orange (figure 4.3B).13 The mixture of nucleotides 
and lanthanide ions has been found to form supramolecular networks which go on to 
form nanoparticles. Energy transfer occurs between the nucleotides and the 
lanthanide ions. These supramolecular networks that are formed upon mixing are 
able to encapsulate gold nanoparticles, as well as proteins and fluorescent dyes.14 
 
 
Figure 4.3: Macrocyclic lanthanide compounds developed for attachment to gold nanoparticles, with 
antennae for self-assembly. A: A macrocyclic europium complex with a diketonate antenna for 






 B: A macrocyclic ytterbium complex with xylenol orange. Figures 





This chapter describes the coating of gold nanoparticles with europium and 
gadolinium complexes. The lanthanide complexes are based on two different DTPA 
bis-amide ligands shown in figure 4.4. The asymmetric lanthanide complex LnQSH 
contains a quinoline chromophore on one arm of the DTPA bis-amide complex and 
an amidothiophenol group on the other arm to provide the thiol for attachment to gold 
nanoparticles. The LnSH complex contains two amidothiophenol arms attached to a 
DTPA backbone to provide two thiols for surface attachment to gold. The EuSH 
complex has previously been reported on gold nanoparticles.15 By co-coating gold 
nanoparticles in a combination of different lanthanide complexes, it is possible to 
develop multi-modal probes utilising the different photophysical properties of the 
lanthanide ions. Gold nanoparticles were coated in both the europium and 
gadolinium analogues of LnSH and for comparison the europium and gadolinium 
analogues of LnQSH. The coated gold nanoparticles exhibit the characteristic 
properties of the lanthanide complexes attached.  
The europium complexes previously reported in chapter three EuNapSAc will be 
discussed for comparison with the two DTPA-bisamide complexes EuSH and 






























2 Results and Discussion 
 
2.1 Preparation and characterisation of EuS.Au and EuQS.Au 
EuS.Au have been prepared following the published procedure.15 The nanoparticles 
were purified by size exclusion chromatography, and the UV-Vis spectra of the 
sample before and after purification shows the same profile but with small dilution 
observed due to the chromatography technique (figure 4.7). The nanoparticles have 
been examined by UV-Vis spectroscopy and luminescence studies. The 
luminescence lifetime of the complex on gold nanoparticles however was found to be 
longer than reported, with a lifetime on nanoparticles found to be 0.5 ms. This lifetime 
is longer than the reported 0.8 µs lifetime and similar to the lifetime of the complex in 
water. Analysis of EuS.Au with inductively coupled plasma optical emission 
spectroscopy (ICP-OES) shows the number of complexes per particle to be 
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Citrate.Au were coated with EuQSH. The synthesis and photophysical 
characterisation of EuQSH complex in methanol is described in chapter 3. Titration of 
a methanolic solution of EuQSH into Citrate.Au gives rise to a 6 nm shift in the 

















































Figure 4.8: UV-Vis titration of EuQSH into Citrate.Au and plot of shift in SPR peak position (B). 
[Citrate.Au] = 2.3 nM. Stock solution of [EuQSH] = 1 mM  in methanol. 
 
 
The luminescence lifetime of EuQSH complex in solution shows similar trends to that 
of the EuSH complex, with the lifetime in methanol measured as 0.8 ms decreasing 
to 0.53 ms in water. This is as expected as water has a higher effect on quenching 
lanthanide luminescence. The luminescence lifetime of the complex recorded on gold 
nanoparticles, EuQS.Au was also found to be 0.53 ms which is the same as the 
complex in water. Upon examination of the UV-Vis spectra before and after 
purification by size exclusion chromatography, the SPR peak position remains at the 




gold nanoparticles remains unchanged after the purification of EuQS.Au and the 
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The EuNapSAc complex used in chapter 3 has a reported luminescence lifetime of 
0.5 ms on gold nanoparticles.16 The lifetime of this free complex in methanol is 
0.82 ms,17 whilst in water it was found to decrease to 0.59 ms. 
The luminescence lifetime of the DTPA bis-amide complexes on bound to gold 
nanoparticles are very similar regardless of the chromophore. This is probably 
because the chelation of the lanthanide is the same throughout the complexes, and 
the complexes all have similar lifetimes in other solutions such as water and 
methanol. This agrees with other comparisons of DTPA bis-amide with different 
chromophores which have similar lifetimes.18 
The binding affinity of the EuSH and EuQSH complexes to gold nanoparticles was 




measuring the thermodynamics parameters of two molecules during complexation. It 
is typically used for the monitoring protein-protein interactions,19 but more recently it 
has been utilised for monitoring the binding of peptides and small molecules to gold 
nanoparticles.20-23 The heat released upon titration of the complexes into a solution of 
Citrate.Au is measured to provide information on the binding interaction. The stock 
solutions of EuSH and EuQSH were dissolved in water containing 10 % methanol. 
Citrate.Au were centrifuged twice and re-suspended in a 10 % methanol solution to 
ensure the two solutions were identical so that the change in heat measured was 









) N  ΔH (cal mol
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EuS.Au 3.09 x 10
6
 ± 4.10 x 10
5
 4610 ± 41.1 -4.08 x 10
4
 ± 616.9 -107 
EuQS.Au 2.63 x 10
6
 ± 4.61 x 10
5
 1690 ± 34.9 -1.055 x 10
4
 ± 330.0 -6.01 
 




Figure 4.10: Isothermal titration calorimetry analysis of the binding of EuSH with Citrate.Au (left) 
and EuQSH with Citrate.Au (right) in water with 10 % methanol. Eu complex was added in µl 
quantities of a 1 mM stock solution to Citrate.Au (concentration = 4.5 nM). Graph A in both 
figures is the raw ITC data for complex - nanoparticle interaction. Graph B is the binding curve 
from the raw data. The squares represent the integrated area of heat change upon binding and 








The ITC data show similar binding constants for the two complexes with gold 
nanoparticles. This could potentially be anticipated as both complexes are of similar 
structure with only a small difference in one of the arms of the DTPA being a 
quinoline in the EuQSH rather than a thiophenol. The EuSH complex with two 
sulphurs has the slightly higher binding constant, possibly due to the presence of the 
extra sulphur. The stoichiometry of complexes to gold nanoparticles (given by the 
value N) obtained from this ITC data are quite different for the two complexes. EuSH 
complex shows a much larger value of 4610 ± 41.1, whilst EuQSH has a 
stoichiometry of 1690 ± 34.9. As this technique measures the gold-sulphur interaction 
between the complex and nanoparticle, it could be anticipated that the EuSH 
complex would have a higher number of interactions per particle as it contains two 
sulphurs. Comparisons of the two values of ΔH, which is the enthalpy change upon 
binding of the complexes to nanoparticles, show that there is a greater enthalpy 
change upon binding of the EuSH to gold nanoparticles compared with EuQSH. This 
is again most likely to be due to a greater number of interactions causing a large 






2.2 Preparation and characterisation of EuS.GdQS.Au 
 
Scheme 4.1: Schematic representation of the preparation of EuS.GdQS.Au 
 
The effect of a combination of two different lanthanide complexes on gold 
nanoparticles was studied by the examination of their photophysical properties. The 
europium complex EuSH and the gadolinium complex GdQSH were added to 
Citrate.Au, with the coating of the Citrate.Au monitored by UV-Vis spectroscopy. 
The nanoparticles were coated by initially titrating in µl aliquots of a 1 mM stock 
solution of EuSH in methanol. Monitoring the SPR band of the gold nanoparticles, a 
6 nm red-shift is observed upon fully coating the Citrate.Au with the complexes. For 
partially coating Citrate.Au, a 1 mM stock solution of EuSH in methanol was added 
at a concentration which resulted in a 3 nm red-shift of the SPR band of the gold 
nanoparticles. A 1 mM stock solution of GdQSH in methanol was then titrated in µl 
aliquots until no further red-shift in the SPR band was observed. Figure 4.11 shows 
the UV-Vis spectra of the EuS.GdQS.Au. The initial addition of 2.5 µM EuSH to 
Citrate.Au gives a red-shift in the SPR of 3 nm, with a further 0.5 nm red-shift upon 








GdQSH complex first at a concentration of 6.6 µM gives the initial red-shift of 3 nm, 
and a further red-shift of 2 nm is observed upon the addition of 9.8 µM EuSH 
complex (figure 4.11B). 
 
 
Figure 4.11: UV-Vis spectroscopy of EuS.GdQS.Au. A: Citrate.Au (), with EuSH (- - -) and 
GdQSH () [EuSH] = 2.5 µM, [GdQSH] = 15 µM, [AuNPs] = 2.25 nM; B: Citrate.Au (), with 
GdQSH () and EuSH (- - -) [GdQSH] = 6.6 µM, [EuSH] = 9.8 µM, [AuNPs] = 2.25 nM 
 
 
Luminescence spectroscopy of the solution of EuS.GdQS.Au shows characteristic 
europium emission upon excitation of the phenol chromophore at 270 nm. The 
europium emission profile remains after purification of the nanoparticles by size 
exclusion chromatography. Interestingly, upon excitation of the quinoline 
chromophore of the GdQSH complex at 310 nm, strong europium emission is still 
observed (figure 4.13). This suggests that the quinoline sensitiser of the GdQSH 
complex is in close proximity of the europium ion to allow excitation to occur. This is 
confirmed by the excitation spectrum of the EuS.GdQS.Au when monitoring the 
europium emission at 614 nm, as it mirrors the profile of the GdQSH complex rather 








































intensity in the region of 270-290 nm compared with the absorption of the QSH 
ligand. This suggests that there is little contribution of the phenol group which 
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Figure 4.12: Excitation spectrum of EuS.GdQS.Au () and UV-Vis spectrum of GdQSH (- - - -) 
and EuSH (). λem = 614 nm.  
 
 
Comparisons of isoabsorptive solutions of EuS.GdQS.Au and EuS.Au show that the 
europium emission intensity is greatly increased in the presence of the GdQSH 
complex at both excitation wavelengths 270 nm and 310 nm. This suggests that the 
GdQSH is responsible for this europium emission intensity increase. Some of the 
luminescence spectra obtained, particularly on weakly emitting samples, show a 
peak attributed to second-order scattering. These have been indicated with an asterix 



















 /nm  
Figure 4.13: Emission spectra of EuS.GdQS.Au λexc = 270 nm (), EuS.GdQS.Au 
λexc = 310 nm (), EuS.Au λexc = 270 nm (− − −), EuS.Au λexc = 310 nm (−
  −
  −) [EuSH] = 2.5 µM; 
[GdQSH] = 15 µM; [AuNPs] = 2.25 nM. Emission spectra corrected for PMT response. Some small 





The luminescence lifetime of the EuS.GdQS.Au was found to be 0.54 ms. This is 
similar to the lifetime of EuQS.Au. To examine the role that the gold nanoparticles 
play in this energy transfer between the two complexes, a control solution of EuSH 
and GdQSH in water has been characterised along with EuS.GdQS.Au and EuS.Au. 
The comparison of EuS.GdQS.Au, EuSH GdQSH in water and EuS.Au is shown in 
figure 4.14. By comparing a solution of EuS.GdQS.Au with a solution of EuSH and 
GdQSH in water at the same concentrations of complexes used in EuS.GdQS.Au 
preparation, it can be observed that the emission intensity of EuS.GdQS.Au is over 
double that of the free complexes in water upon excitation of the quinoline moiety at 
λexc = 310 nm (figure 4.14B). The two complexes mixed in solution show a small 






be occurring in solution. This solution of EuSH and GdQSH in water exhibits weak 
europium emission upon excitation at λexc = 310 nm, possibly due to the formation of 
disulphide bonds between the two complexes. The emission spectrum for EuS.Au 
shows no europium emission at the concentrations used to prepare EuS.GdQS.Au 
at either excitation wavelengths λexc = 270 nm or 310 nm. 
 

































Figure 4.14: Emission spectra of EuS.GdQS.Au (- - - -), EuSH GdQSH in water () and 
EuS.Au (). A: λexc = 270 nm. B: λexc = 310 nm. [EuSH] = 2.5 µM; [GdQSH] = 1.5 µM; [AuNPs] = 
2.25 nM. Emission spectra corrected for PMT response. * indicates second-order scattering peaks (A 




Preliminary experiments found that the europium emission intensity increase of 
EuS.GdQS.Au occurs over a period of time. To investigate this, EuS.GdQS.Au was 
also monitored by UV-Vis spectroscopy over time to monitor any changes to the SPR 
band as the complexes attach to the nanoparticle surface. An initial scan of 
Citrate.Au was taken by UV-Vis spectroscopy, then a methanolic solution of EuSH 






hours. Figure 4.15 shows the UV-Vis spectra of a solution of EuS.GdQS.Au 
monitored over time, with a plot of the shift in λmax of the SPR band taken from the 
derivative of the curve. After the initial red-shift upon addition of the complexes to 
Citrate.Au, the SPR band exhibits a further 1 nm red-shift over time. This suggests 
that there is a large interaction initially on the nanoparticle surface, and then further 
rearrangement may occur over a longer period of time.  
 
Figure 4.15: UV-Vis spectra and plot of SPR band λmax shift of EuS.GdQS.Au taken over 18 hours. 
Inset: SPR band between 490-560 nm. [EuSH] = 6.6 µM, [GdQSH] = 6.6 µM, [AuNPs] = 1.3 nM. 
 
 
The europium emission intensity of the EuS.GdQS.Au was also monitored over time. 
This was carried out by monitoring the strongest peak at 614 nm which is attributed 
to the 5D0 → 
7F2 transition of europium. Figure 4.16 shows the increase in europium 
emission intensity over 24 hours. The initial mixing of the two complexes with and 
without gold nanoparticles show the same emission spectra, with no europium 
emission observed. Integration of the peak area of the emission spectra of 



























































intensity is nearly four times greater than the two complexes mixed in water after 24 
hours. Hydrazine monohydrate was added to both solutions to reduce any disulphide 
bonds formed between the two different complexes, which could allow for the 
quinoline sensitiser of the GdQSH complex to become in close proximity to the 
europium ion of the EuSH complex. Therefore the gold nanoparticle appears to 
provide a good scaffold for the assembly of these two complexes in close enough 










Figure 4.16: Timebased emission studies of EuS.GdQS.Au and EuSH GdQSH in water. 
λexc = 320 nm; λem = 614 nm. A: Europium emission intensity monitored at 614 nm. B: steady state 
emission spectra of EuS.GdQS.Au at 0 hrs () and 24 hrs (− − −) and EuSH GdQSH in water at 
0 hrs () and 24 hrs (). [EuSH] = 6.6 µM, [GdQSH] = 6.6 µM, [AuNPs] = 1.3 nM. 
 
 
In order to confirm that this phenomenon occurs with the two complexes on the same 
nanoparticle, fully coated EuS.Au and GdQS.Au were prepared and combined in 
order to investigate their photophysical properties. The nanoparticle samples were 
passed through a size exclusion chromatography column to remove any excess 
complex in solution. Upon excitation of a mixture of EuS.Au and GdQS.Au at 
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λexc = 320 nm, the nanoparticles exhibit no europium emission. This suggests that the 
two complexes need to be on the same nanoparticle in order for the europium ion to 
be sensitised by the quinoline. It is likely that the increase in europium emission 
observed is not caused by transmetallation of the lanthanide complexes, as this is 
likely to occur upon mixing of EuS.Au and GdQS.Au.  
Further studies into the energy transfer on gold nanoparticles were carried out by 
adding just the QSH ligand onto gold nanoparticles with EuSH, in order to ascertain 
whether energy transfer occurs without the presence of the gadolinium in the 
complex. Citrate.Au were coated in EuSH complex at a concentration of 2.9 µM as 
previously described giving a red-shift in the SPR band of the gold nanoparticles of 
3 nm. Then a solution of the free QSH ligand in methanol was titrated into the 
nanoparticles to give a final concentration of QSH of 9.9 µM, resulting in a further 
1 nm red-shift. The emission spectra of the EuS.QS.Au when exciting the phenol 
group of the EuSH at λexc = 270 nm and exciting the quinoline at λexc = 310 nm both 
show the characteristic emission profile for europium (figure 4.17A). The excitation 
spectrum of a solution of EuS.QS.Au monitoring the europium band at 614 nm also 
agrees with the UV-Vis profile for the QSH ligand, suggesting that the europium 
emission is being sensitised by the quinoline chromophore of the QSH ligand 












































































Figure 4.17: Photophysical studies of EuS.QS.Au after size exclusion chromatography. 
[EuSH] = 2.9 µM, [QSH ligand] = 9.9 µM, [AuNPs] = 2.25 nM. A: Emission spectra of nanoparticles 
λexc = 270 nm () and λexc = 310 nm (−−−). B: Excitation spectrum of EuS.QS.Au () 




For comparison, EuS.GdS.Au, EuQS.GdQS.Au and EuQS.GdS.Au were prepared 
following a similar procedure to EuS.GdQS.Au. The nanoparticles were prepared 
and their photophysical properties were investigated to examine the effects of the 
co-coating Citrate.Au with these combinations of lanthanide complexes. These 








2.3 Preparation and characterisation of EuS.GdS.Au 
 
Scheme 4.2: Schematic representation of the preparation of EuS.GdS.Au 
 
To prepare mixed complex coated gold nanoparticles, Citrate.Au were coated with 
the europium and gadolinium complex EuSH and GdSH. The gold nanoparticles are 
coated by adding µl additions of a methanol stock solution of the complexes and 
purified by size exclusion chromatography. The final concentrations titrated into 
Citrate.Au were 9.9 µM EuSH and 6.6 µM GdSH. The additions of the two 
complexes to Citrate.Au were monitored by UV-Vis spectroscopy, with the position 
of the maximum absorption wavelength of the SPR band red-shifting upon addition of 
the methanolic lanthanide complex solution. The initial shift upon addition of the 
EuSH complex is 4 nm, with a small red-shift of approximately 0.5 nm upon addition 
of the GdSH complex (figure 4.18). The final SPR shift observed is a 4.5 nm red-shift, 
which is less than that of fully coated EuS.Au which has a red-shift in the SPR band 

























Figure 4.18: UV-Vis spectra of the preparation of EuS.GdS.Au. Citrate.Au (− − −) with the addition 
of EuSH () and GdSH () [EuSH] = 9.9 µM, [GdSH] = 6.6 µM, [AuNPs] = 4.5 nM 
 
 
Figure 4.19 shows EuS.GdS.Au before purification by size exclusion 
chromatography and EuS.Au at the same concentration of EuSH as used in the 
preparation of EuS.GdS.Au. The emission of the EuS.GdS.Au is of similar intensity 
to EuS.Au, even though the signal is weak in comparison to other samples prepared. 
This suggests that the mixing of EuSH and GdSH has little effect on the emissive 
properties of the EuSH complex on gold nanoparticles, as the nanoparticles exhibit 
the characteristic photophysical properties of europium. The luminescence lifetime of 
the europium complex on the dual coated gold nanoparticles is 0.56 ms, which is 
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Figure 4.19: Emission spectra of EuS.GdS.Au () before purification by size exclusion 
chromatography and EuS.Au (). λexc = 270 nm. [EuSH] = 9.9 µM, [GdSH] = 6.6 µM. 




2.4 Preparation and characterisation of EuQS.GdQS.Au 
 
Scheme 4.3: Schematic representation of the preparation of EuQS.GdQS.Au 
 
Citrate.Au were coated in the lanthanide complexes EuQSH and GdQSH. The 









in the SPR band of the gold nanoparticles. A 1 mM stock solution of EuQSH in 
methanol was titrated into Citrate.Au to give a red-shift of 3 nm, and a further 
red-shift of 1.5 nm was observed upon titration of a 1 mM stock solution of GdQSH 
complex in methanol (figure 4.20). The final concentrations of complexes added to 
prepare EuQS.GdQS.Au were 5.8 µM EuQSH and 5.8 µM GdQSH. In comparison 
with fully coated EuQS.Au which has an observed red-shift of 6 nm, the effect of 
coating gold nanoparticles with two different LnQSH complexes is a resulting smaller 
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Figure 4.20: UV-Vis spectra of preparation of EuQS.GdQS.Au. Citrate.Au () with the addition of 
EuQSH (− − −) and GdQSH () Final concentrations: [EuQSH] = 5.8 µM, [GdQSH] = 5.8 µM, 
[AuNPs] = 4.5 nM 
 
Studies of the photophysical properties of EuQS.GdQS.Au show the characteristic 
peak of europium upon excitation of the quinoline. The luminescence lifetime of 
EuQS.GdQS.Au was recorded as 0.53 ms. Figure 4.22A shows the emission spectra 
of EuQS.GdQS.Au as prepared and after purification by size exclusion 




prepare EuQS.GdQS.Au was added to Citrate.Au. The excitation spectra matches 
the profile of the UV-Vis spectrum of the QSH ligand, which is as to be expected as 
the quinoline should be responsible for the sensitisation of the europium ions. The 
europium emission of the EuQS.GdQS.Au after purification decreases which is due 
to the removal of excess complexes and the dilution of the sample due to the 
purification method. Comparison of the UV-Vis spectra before and after purification 
by size exclusion chromatography also shows no change in the SPR peak position at 
524.5 nm, suggesting that there has been no change to the surface of the 
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Figure 4.21: UV-Vis spectra of EuQS.GdQS.Au before () and after (− − −) size exclusion 
chromatography. 
 
The luminescence studies of EuQS.GdQS.Au show a decrease in europium 
emission intensity upon purification of the nanoparticles (figure 4.22A). The 
percentage decrease in europium emission intensity calculated by integrating the two 
spectra shown in figure 4.22A is 44 %. This is quite close to the percentage decrease 




spectroscopy, which suggests that the emission intensity decrease can be partially 
attributed to the dilution of the nanoparticles by size exclusion chromatography, as 
well as the removal of excess unbound complex. A comparison of the europium 
emission intensity of EuQS.GdQS.Au before purification with EuQS.Au at the same 
concentration shows higher europium emission intensity for the sample containing 
the GdQSH complex. Interestingly, the europium emission from the EuQS.GdQS.Au 
before purification was 2.5 times greater than that of EuQS.Au containing the same 
concentration of EuQSH. The two solutions were isoabsorptive at the excitation 
wavelength of 310 nm, therefore this suggests that whilst there is the same 
concentration of EuQSH in both nanoparticle samples, the GdQSH complex appears 
to be causing an increase in the emission from the europium on the gold 
nanoparticles.  
 

































Figure 4.22: A: Emission spectra of EuQS.GdQS.Au before (− − −) and after purification by size 
exclusion chromatography (). B: EuQS.GdQS.Au before purification and EuQS.Au prepared 
with the same concentration of EuQSH used in EuQS.GdQS.Au ().λexc = 310 nm. Spectra 





2.5 Preparation and characterisation of EuQS.GdS.Au 
 
Scheme 4.4: Schematic representation of the preparation of EuQS.GdS.Au 
 
EuQS.GdS.Au have been prepare by coating Citrate.Au with EuQSH and GdSH 
complexes. The coating of Citrate.Au was monitored by UV-Vis spectroscopy. The 
coating procedure was similar to that of EuS.GdQS.Au. Briefly, a solution of EuQSH 
in methanol was titrated into Citrate.Au to give half the total shift observed upon fully 
coating the gold nanoparticles. Then GdSH is added to give a further shift in the SPR 
band. This procedure was repeated in reverse, by adding GdSH first then EuQSH. 
The titration of µl aliquots of a 1 mM stock solution of EuQSH to Citrate.Au gives a 
3 nm red-shift and a final concentration of EuQSH of 6.5 µM. To this solution, a stock 
solution of GdSH was added at a final concentration of 9.8 µM causing a further 
0.5 nm red-shift in the SPR band (figure 4.23A). Alternatively addition of GdSH to the 
gold nanoparticles first gives a 2.5 nm red-shift as expected, with a further 1.5 nm 






















Figure 4.23: UV-Vis spectra of EuQS.GdS.Au. A: EuQS.GdS.Au: Citrate.Au () with the addition 
of EuQSH (− − −) and GdSH (). B: GdS.EuQS.Au: Citrate.Au () with the addition of 
GdSH () and EuQSH (− − −). [EuQSH] = 6.5 µM; [GdSH] = 9.8 µM; [AuNPs] = 4.5 nM. 
 
 
Despite the difference in shifts in the SPR band of the gold nanoparticles depending 
on the order in which the complexes are titrated in, the emission profile of the 
nanoparticles are the same after purification by size exclusion chromatography. This 
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Figure 4.24: Comparison of EuQS.Au (), EuQS.GdS.Au (− − −), GdS.Au () and 
GdS.EuQS.Au (). [EuQSH] = 6.5 µM; [GdSH] = 9.8 µM; [AuNPs] = 4.5 nM. λexc = 310 nm. 
Spectra corrected for PMT response. The spectra for GdS.Au shows a small second order scattering 
peak at 620 nm, indicated by *. 
 
 
Comparison of the luminescence spectra of the two samples before size exclusion 
chromatography shows an interesting trend (figure 4.24). There is a 35 % increase in 
europium emission intensity when the GdSH complex is titrated into the Citrate.Au 
first followed by the EuQSH complex rather than titrating in EuQSH first to the 
Citrate.Au. The EuQS.GdS.Au co-coated nanoparticles show a 67 % increase in 
europium emission than the EuQS.Au coated with EuQSH at the same 
concentration. This suggests that the presence of the GdSH improves the europium 
emission intensity of the EuQSH complex in EuQS.GdS.Au. Mixing of the two free 
complexes in water does not show any enhancement in luminescence intensity of 
europium, suggesting that the gold nanoparticles contribute to the greater europium 







Gold nanoparticles have been successfully coated in europium complexes and a 
mixture of europium and gadolinium complexes. The photophysical properties of the 
two europium complexes EuSH and EuQSH have been compared on gold 
nanoparticles. Dual coated gold nanoparticles were prepared using the europium and 
gadolinium complexes of the SH and QSH ligand. Lanthanide complexes based on 
the two different DTPA bisamide ligands were used for complexing the lanthanide 
ions, and the combination of different lanthanide complexes appear to effect the 
photophysical properties of the europium complexes on the gold nanoparticle 
surface. The table below summarises the effect of co-coating gold nanoparticles with 
the different lanthanide complexes on the excitation wavelength required to observe 
europium emission (table 4.2). 
 
 Europium emission observed 
λexc = 270 nm λexc = 310 nm 
EuS.Au  
EuS.GdS.Au   
EuS.GdQS.Au  
EuQS.Au   
EuQS.GdS.Au   
EuQS.GdQS.Au   
Table 4.2: Summary of the europium emission observed at the excitation wavelengths 270 nm and 
310 nm. 
 
The most interesting result was obtained from EuS.GdQS.Au. Europium 
luminescence from the EuSH complex was only observed at the higher excitation 
wavelength of 310 nm in the presence of the GdQSH.  Some energy transfer was 




EuSH complex when the two complexes were used to coat gold nanoparticles. The 
gold nanoparticles appear to provide a suitable platform for this energy transfer to 
occur, as they provide a large surface area for many of the different probes to bind 
and interact with one another. All the complexes appear to show some interaction 
upon mixing, with the emissive properties of the europium complex on nanoparticles 








3.1 Preparation of lanthanide coated gold nanoparticles 
Gold nanoparticles used for these experiments were 13 nm citrate stabilised gold 
nanoparticles. A 1 mM stock solution of lanthanide complexes were prepared by 
dissolving the complex in methanol. These solutions were titrated into gold 
nanoparticles in µl aliquots and the coating of nanoparticles was monitored by UV-Vis 
spectroscopy. 
Time-based emission studies were carried out with stirring with the addition of the 
two complexes. Hydrazine monohydrate was also added to prevent the formation of 
disulphide bonds between complexes. 
 
3.2 Isothermal calorimetry 
Isothermal calorimetry was carried out on a Microcal VP-ITC isothermal titration 
calorimeter. Data analysis was performed using Origin 7 Microcal software. In a 
typical experiment, the europium complex dissolved in water containing 10 % 
methanol and injected in µl quantities into citrate stabilised gold nanoparticles 
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New sensitiser for near infrared lanthanides 
 
1 Introduction 
Lanthanides that emit in the near-infrared are of interest for imaging of biological 
systems. There is an interest to develop these probes to improve sensitivity and 
overcome the challenges faced with imaging probes that emit in the visible region. 
Tissue and blood can absorb light in the visible region, which can mean that the light 
emitted from visible probes can be reabsorbed by biological molecules and tissue. 
Skin and other tissue is transparent to near-infrared light, which makes imaging with 
near-infrared complexes desirable to improve the detection of the light emitted from 
the cellular probe. Near-infrared probes also have excited states lower in energy than 
the visible lanthanides, thus requiring lower energy for excitation. This allows for the 
use of a chromophore that can be excited in the visible region. Near-infrared 
complexes have shorter luminescence lifetimes compared with visible lanthanide, but 
they are still suitable for time-gated experiments. Emission in the near-infrared region 
is desirable as biological systems do not contain anything that emit in the near-
infrared region, and the Stokes shift between the excitation source and the 
lanthanide emission is significantly large enough to prevent any light from the 
excitation source being detected.1   
Developing a sensitiser for near-infrared lanthanides allows for the use of a 
chromophore that absorbs in the visible region, which is desirable for cellular imaging 
as excitation above 340 nm is compatible with the optics of the microscope and 
avoids absorption of the excitation light by some common biomolecules in the cell.2 




primary focus being on developing sensitisers that can be excited in the visible 
region.3-5 Pope et al. utilised an anthraquinone sensitiser attached to a tetra-alkylated 
cyclen derivative for chelation of the near-infrared lanthanides neodymium, ytterbium 
and erbium (figure 5.1).3 Increasing the pH of this anthraquinone complex was found 
to induce a bathochromic shift in the absorbance profile, allowing the sensitisation of 
the near-infrared lanthanides at an excitation wavelength of 575 nm. Xylenol orange 
has also been investigated as a sensitiser for an ytterbium complex on gold 
nanoparticles, which was found to exhibit an ‘on-off’ effect as a result of change in 
pH.6 Excitation of this complex at pH greater than 4 was achieved with 580 nm light. 
 
 
Figure 5.1: A: Near-infrared lanthanide complex with anthraquinone sensitiser. Ln = Nd, Yb or Er.
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Transition metal complexes have also been used as sensitisers for near-infrared 
lanthanides. The excitation of near-infrared lanthanides with tethered transition metal 
complexes is also widely studied.7-14 The advantages of using transition metal 
chromophores are that they are strongly absorbing in visible region, and have 
relatively long-lived triplet excited states which aids energy transfer to the attached 
lanthanide.9 One of the first examples of this was the report of neodymium and 
ytterbium complexes with sensitisation from the transition metal complexes ruthenium 
(II) tris(bipyridine) or ferrocene (figure 5.2).10 The ruthenium complex allows for 
excitation with visible light at 450 nm, whilst the ferrocene sensitiser has much lower 
absorption in the visible region its triplet state of 13300 cm-1 is still close to that of the 
receiving luminescent states of the near-infrared lanthanides neodymium 
(11300 cm-1) and ytterbium (10200 cm-1). Both systems were found to give rise to 
near-infrared emission from neodymium and ytterbium with excitation wavelengths of 
450 nm for the ruthenium complex and 320 nm for ferrocene. 
 
 
Figure 5.2: Structure of near-infrared lanthanide complexes with transition metal sensitisers.
10
 A: 
Ruthenium (II) tris(bipyridine) m-terphenyl-based lanthanide complex.  B: Ferrocene 










Faulkner et al. reported the synthesis of a heterometallic lanthanide complex with an 
adjoining azo-dye containing neodymium and ytterbium (figure 5.3).15 The lanthanide 
ions are complexed within a well-known chelator DO3A. The azo-dye acts as the 
chromophore for the tethered near-infrared lanthanide complexes which allows for 
visible light excitation. Monitoring the emission using time-gated emission 
spectroscopy shows the characteristic emission profile for neodymium and ytterbium 
upon excitation of the bimetallic complex at 420 nm.  
 
 
Figure 5.3: Structure of polymetallic lanthanide complexes with azo-dye linker.
15
 Ln and Ln’ = Nd or Yb 
 
 
The previous chapters have shown that the SH and QSH ligands are suitable for the 
sensitisation of neodymium. These complexes however are limited by the 
wavelengths at which the chromophore can be excited, with an excitation wavelength 




extensive conjugation for higher absorption coefficients in the visible region. 
Kobrakov et al. reported the synthesis and characterisation of an azo-dye which was 
tested for its ability to be used as a fabric dye.16 This azo-dye was selected for the 
studies in this chapter due to its high absorption coefficient, and it was postulated 
that it would be suitable for use as a near-infrared lanthanides sensitiser. The high 
absorption in the visible region allows for the possibility of excitation of the azo-dye at 
wavelengths greater than 400 nm. Whilst the synthesis of these dyes is reported with 
many steps, each step goes forward in quite high yields which make them quite easy 
to prepare in large quantities. There have been few examples of azo-dyes being 
utilised as sensitisers for near-infrared lanthanides.15 This chapter reports the 
synthesis of the azo-dye (E)-4-((2-hydroxy-5-nitrophenyl) diazenyl)-1-(2-methoxy-5-
nitrophenyl)-3-methyl-1H-pyrazol-5-ol (compound 5) and its use as a sensitiser for 
near-infrared lanthanides (figure 5.4). The azo-dye compound 5 was reacted with 
the near-infrared lanthanides neodymium and ytterbium and the photophysical 






Figure 5.4: Schematic diagram of the reaction of the azo-dye prepared in this chapter with Ln(III) ions 
and the suggested mode of complexation. Ln = ytterbium and neodymium 
 




2 Results and Discussion 




nitrophenyl)-3-methyl-1H-pyrazol-5-ol (compound 5) was prepared following the 
reaction scheme showed in figure 5.5. I was prepared following published 





Figure 5.5: Reaction scheme of synthesis of (E)-4-((2-hydroxy-5-nitrophenyl)diazenyl)-1-(2-methoxy-5-
nitrophenyl)-3-methyl-1H-pyrazol-5-ol (Compound 5). 
 
 
The synthesis proceeds following the scheme shown in figure 5.5, with the 
conversion of 2-methoxy-5-nitrophenylaniline to 2-methoxy-5-nitrophenyl hydrazine 
firstly by the diazotisation of the starting material using sodium nitrite in the presence 
of HCl. The diazonium salt was then reduced using tin (II) chloride to give the product 
at a 34 % yield. The 1H NMR spectrum shows peaks at 6.78 and 3.60 ppm 
corresponding to the protons bound to the NH and NH2 groups. Integration of the 
  
  
Compound 1 Compound 2 






peaks gives the appropriate number of protons and agrees with the published 
procedure.  
The next synthetic step is the reaction of the hydrazine compound 1 with 
ethylacetoacetate to form the pyrazole. The intermediate product of this reaction 
(compound 2) can be isolated after 10 minutes reflux in ethanol in the presence of 
HCl. The final product, 1-(2-methoxy-5-nitrophenyl)-3-methyl-1H-pyrazol-5-ol 
(compound 3) was isolated after 3 hours reflux in ethanol in the presence of HCl. 
Comparisons of the 1H NMR spectra of compound 2 and 3 (figure 5.6) shows the 
change in structure as the reaction proceeds, with the loss of the proton bound to the 
nitrogen and the peak associated with proton H3 shifting downfield upon the 
formation of the pyrazole. Also there is the loss of the protons H8 and H9 as the ethyl 
chain is lost upon formation of the pyrazole. Both 1H NMR spectra integrate for the 







H NMR spectra of compounds 2 and 3 in CDCl3. A: 
1
H NMR of compound 2. B: 
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The reaction for the formation of compound 4 proceeds with the addition of sodium 
nitrite to a solution of 2-amino-4-nitrophenol in water. The bright yellow compound 
was found to be prone to decomposition at room temperature and was used 
immediately upon preparation for the final step of synthesis of the azo-dye. 
The final step in the synthesis of the azo-dye involves the slow addition of the 
diazonium salt (compound 4) into an ethanolic solution of compound 3. The 
complex was characterised by mass spectrometry and NMR spectroscopy. The mass 
spectrum showed a peak at 413 m/z corresponding to the molecular weight of the 
product and a peak at 437 m/z corresponding to the sodium adduct. The 1H NMR of 








H NMR spectrum of final azo-dye, compound 5 in D6-DMSO 
 
 
The UV-Vis and fluorescence spectra of the azo-dye are presented in figure 5.8. The 
UV-Vis spectrum shows peaks at 256 nm, 300 nm and 416 nm. Previously observed 
UV-Vis spectra of azo-derivatives suggests that these peaks can be attributed to 
π → π* transitions (256 nm) and n →π* transitions (300 nm and 416 nm).15 Upon 
























































































2.2 Preparation and characterisation of neodymium and ytterbium 
complexes with compound 5: Ln(Azo)  
The complexes Ln(Azo) were prepared by addition of LnCl3.6H2O (where 
Ln = Nd or Yb) into a solution of the azo-dye. These complexes give rise to the 
characteristic lanthanide ion emission when excited at λexc = 450 nm, shown in 
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Figure 5.9: Luminescence spectra of Nd(Azo) and Yb(Azo) in ethanol. λexc = 450 nm. [Azo] = 0.3 mM, 
[LnCl3.6H2O] = 0.1 mM. 
 
By monitoring the titration of lanthanides into a solution of the azo-dye, it should be 
possible to estimate how many of the azo-dyes are coordinating the lanthanide. Upon 
addition of the lanthanide solution to the azo-dye, there is an obvious change in the 
UV-Vis spectrum (figure 5.10). This is visible by eye, as the solution turns from 
orange to bright yellow. Titration of Yb3+ into the azo-dye solution causes a dramatic 
change in the UV-Vis spectrum, with the band at 416 nm shifting to 465 nm. A plot of 
the shift in this band is shown in figure 5.10. This large red-shift in the absorbance 
profile of the complex allows for the use of excitation wavelengths in the visible 
region up to 500 nm. The shift in the UV-Vis spectrum appears to stop after the 
addition of 0.13 mM of YbCl3.6H2O. This stabilisation of the UV-Vis profile suggests 
that all the azo-dye is bound to Yb3+. The ratio of azo-dye to ytterbium is 3:1 which 
suggests that three azo-dyes are bound to one Yb3+ forming a complex. The profile 































Figure 5.10: UV-Vis titration of Yb
3+
 into the azo-dye. [Azo] = 0.417 mM in ethanol (), 
[YbCl3.6H2O] = 0.019-0.185 mM. Arrows indicate the direction of shift upon titration of Yb. 
 
 
The luminescence of the sample should also provide a good indication of the 
coordination, as the lanthanide itself cannot be directly excited at 450 nm, so once all 
the azo-dye has been coordinated there should be saturation of the luminescence 
signal. The titration of Yb3+ into the azo-dye is shown in figures 5.10 and 5.11, with 
both the absorbance and luminescence being monitored during the titration 
(figure 5.11). Figure 5.11 shows the luminescence spectra of the titration of Yb3+ into 
the azo-dye. The titration curve for the luminescence is slightly different in profile, but 
they seem to plateau at similar concentrations, agreeing with the 3:1 ratio observed 






































Figure 5.11: Luminescence titration of Yb
3+
into azo-dye. [Azo] = 0.417 mM. [YbCl3.6H2O] = 0.019-
0.185 mM.  λexc = 450 nm 
 
 
The luminescence titration of Nd3+ into the azo-dye gives a similar ratio to that 
observed with the Yb3+ with 3 azo-dyes to 1 Nd3+ ion (shown in figure 5.12). This is 
as expected as all the lanthanides ions have similar coordination. The plot of the 
relative emission increase was calculated from the growth of the strongest peak at 
1056 nm which is associated with the 4F3/2 → 
4I11/2 transition.  
 
 






































Figure 5.12: Titration of Nd
3+
 into azo-dye in ethanol. [Azo] = 0.3 mM, [NdCl3.6H2O] = 0.022 – 
0.32 mM.  λexc = 450 nm.  
 
 
The lifetimes of Nd(Azo) and Yb(Azo) in ethanol was found to be 8 µs and 10 µs 
respectively. The absorbance at higher wavelength upon lanthanide complexation 
allows for excitation with visible light at wavelengths as high as 500 nm (figure 5.13).  
 






























Figure 5.13: Luminescence spectra of azo-dye complexes upon excitation at λexc = 500 nm.  
Left: Nd(Azo). [Azo] = 0.3 mM, [NdCl3.6H2O] = 0.022 – 0.32 mM. Right: Yb(Azo). [Azo] = 0.417 mM, 
[YbCl3.6H2O] = 0.185 mM 
 























The azo-dye mixed with lanthanides that emit in the visible region such as europium 
and terbium did not give rise to emission from the lanthanide ion. This could be due 
to the triplet state of the azo-dye being too low for excitation of these lanthanides. It is 
possible if some emission did occur it would be masked by the emission observed 
from the azo-dye itself, which emits in a similar region to the visible lanthanides with 
a broad peak. The near-infrared lanthanides have much lower excited states than the 
visible lanthanide which may make them easier to excite with this azo-dye. Mixing the 
azo-dye with erbium does not give rise to any erbium emission upon excitation at 





An azo-dye has been synthesised and characterised following a five step synthesis. 
The azo-dye was found to be suitable for use as a sensitiser for the near-infrared 
lanthanides neodymium and ytterbium, allowing excitation using visible light up to 
500 nm. Titration of lanthanide into a solution of the azo-dye suggests that the 
azo-dye forms a complex with the lanthanide at a ratio of 3:1 azo-dye to lanthanide. 
This azo-dye sensitiser can be developed further by modification to allow for 
attachment to a strongly chelating ligand, such as DTPA. This would allow for the 
lanthanide to form a more stable complex, whilst still being in close proximity to the 
azo-dye for sensitisation.  Initial attempts to reduce the nitro groups to amines failed 




possible that this reduction could be carried out on one of the starting materials to try 
and obtain this amine derivative. The development of an assymetric probe with this 
azo-dye would also allow for the attachment of a surface-active group for attachment 





3.1 Synthesis of 2-methoxy-5-nitrophenyl hydrazine16 
 
2-methoxy-5-nitrophenylaniline (5 g, 29 mmol) was added to 85 ml 12 M HCl at 0oC. 
A solution of sodium nitrite (2.3 g, 33 mmol) in 13 ml water was added drop-wise to 
the reaction mixture to ensure the internal temperature was kept below 10oC. Once 
the addition was complete, the solution was cooled further using a dry ice/ acetone 
bath. A solution of SnCl2.2H2O (15 g, 66 mmol) in 15 ml HCl was added slowly to the 
reaction mixture. A further 25 ml HCl was added to the reaction to aid stirring and the 
solution was stirred for 25 mins. The precipitate formed was filtered and was stirred 
into 100 ml of a 25 % KOH solution. The orange precipitate formed was collected and 
stirred in ethyl acetate. The ethyl acetate solution was washed with water (1 x 50 ml), 
brine (1 x 50 ml) and dried with MgSO4. The ethyl acetate was removed in vacuo and 
the product recrystallized from 100 ml methanol (1.83 g, 34 %). 
1H NMR (300 MHz, CDCl3) δ (ppm) 7.85 (1H, d, ArH), 7.71 (1H, dd, ArH), 6.78 (1H, 
d, ArH), 5.81 (1H, s, NH), 3.94 (3H, s, OCH3), 3.60 (2H, s, NH2).   




3.2 Synthesis of acetoacetic ester 2-methoxy-5-nitrophenyl hydrazone 
 
2-methyoxy-5-nitrophenyl hydrazine (0.91 g, 5 mmol) and ethylacetoacetate (0.64 g, 
5 mmol) were refluxed for 10 minutes in ethanol (10 ml) with the addition of a few 
drops conc. HCl. The solution was allowed to cool, yielding a yellow precipitate. 
(0.836 g, 58 %) 1H NMR (300 MHz, CDCl3) δ (ppm) 8.23 (1H, d, ArH), 7.75 (1H, dd, 
ArH), 7.52 (1H, s, NH), 6.84 (1H, d, ArH), 4.21 (2H, q, CH2CH3), 3.98 (3H, s, CH3O), 
3.42 (2H, s, CCH2C), 2.01 (3H, s, CH3C) , 1.31 (3H, t, CH2CH3); MS (ES+): m/z 318 
[M+Na]+ 




3.3 Synthesis of 3-methyl-1-(2-methoxy-5-nitrophenyl)-1H-pyrazol-5-ol 
 
2-methyoxy-5-nitrophenyl hydrazine (0.7 g, 4 mmol) and ethylacetoacetate (0.48 g, 4 
mmol) were refluxed for 12 hours in ethanol (50 ml) with the addition of a few drops 
conc. HCl. Solvent was removed in vacuo to give yellow oil which was a mixture of 
two products. The oil was redissolved in 10 ml water and the pH adjusted to 14. The 
solution was washed with DCM (2 x 20 ml). The aqueous layer was then acidified 
and washed with DCM (2 x 20 ml). The organic layer was retained and the solvent 




1H NMR (300 MHz, CDCl3) δ (ppm) 8.28 (2H, m, ArH), 7.08 (1H, d, ArH), 3.97 (3H, s, 
OCH3), 3.42 (2H, s, CH2), 2.20 (3H, s, CH3); 
13C NMR (400 MHz, CDCl3) δ (ppm) 
125.6, 124.2, 111.7, 56.8, 41.4, 14.6;  MS (ES+): m/z 250 [M+H]+ 
 
 
3.4 Synthesis of 2-hydroxy-5-nitrophenyl diazonium 
 
2-amino-4-nitrophenol (0.51 g, 3 mmol) was stirred into 50 ml 1 M HCl at 0oC Sodium 
nitrite (0.226 g, 3mmol) in 15 ml water was added drop-wise to the reaction mixture. 
A yellow precipitate formed in the solution which was stirred for 30 minutes. The 
precipitate was collected by suction filtration and used immediately in the next 











3-methyl-1-(2-methoxy-5-nitrophenyl)-1H-pyrazol-5-ol (0.081g, 0.3 mmol) was 
dissolved in ethanol and heated to 80oC. Sodium hydroxide (0.013 g, 0.3 mmol) and 
sodium acetate (0.064 g, 0.8 mmol) were added and the solution was cooled to 0oC. 
A suspension of 2-hydroxy-5-nitrophenyl diazonium (0.054 g, 0.3 mmol) in 10 ml 
ethanol was added slowly over 15 minutes. The pH was monitored and kept basic 
with 10 % NaOH. After the addition was complete, the reaction mixture was stirred for 
2 hours. The solution was acidified to pH 5-6 and precipitate was collected by suction 
filtration. (0.061 g, 45 %). 1H NMR (300 MHz, D6-DMSO) δ (ppm) 8.39 (2H, d), 8.37 
(1H, d), 8.01 (1H, dd), 7.46 (1H, d), 7.11 (1H, d), 3.94 (3H, s), 2.33 (3H, s) MS (ES+): 
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1 Materials and Methods 
All chemicals were purchased from Sigma Aldrich or Fisher Scientific and used 
without further purification unless otherwise stated. Solvents were purchased from 
Sigma Aldrich and Fisher. HPLC grade solvents were used in photophysical studies. 
Water was deionised using an Elga Option 3 water purifier. 
 
2 Equipment 
2.1 NMR and Mass spectrometry 
1H and 13C NMR were recorded on Brüker AVIII300 and AVIII400 spectrometers. 
SiMe4 was used for an external reference of the 1H and 13C shifts. Deuterated 
solvents were obtained from Goss Scientific and used as supplied. 
Matrix assisted laser desorption ionisation – time of flight (MALDI-TOF) mass 
spectrometry was carried out on a Brüker Biflex IV mass spectrometer, using 
Gentisic acid in CH3CN with 0.1% TFA as the matrix. Electrospray mass 
spectrometry was carried out on a Micromass LC-TOF. 
 
2.2 HPLC 
HPLC was carried out on a Dionex summit system, using a Summit P580 quaternary 
low pressure gradient pump with built-in vacuum degasser. The detector was a 
Summit UVD 170s UV-VIS multi-channel detector with analytical flow cell for 
analytical HPLC and a prep flow cell for semi-prep HPLC.  The column used for 




column (250 mm x 4.6 mm). The column used for semi-prep HPLC was the 
Phenomenex Luna 10 μm particle size C18 semi-prep column (250 mm x 10 mm). All 
solvents used were HPLC grade solvents, degassed prior to use. 
 
2.3 UV-Vis Spectroscopy 
UV-Vis absorption spectra were carried out on Varian Cary 50 or Varian Cary 5000 
spectrometers with 300 nm/min UV-vis spectra were taken using 1 cm path length 
quartz cuvettes.  
 
2.4 Luminescence Spectroscopy 
Luminescence studies were carried out on a PTI fluorescence system, using a PTI L-
201M with a 75 W xenon arc lamp as the illumination source. The detection system 
was a Shimadzu R928 PMT in a PTI model 814 analogue/photon counting 
photomultiplier. The emission monochromator is equipped with two interchangeable 
blazed gratings at 500 nm and 750 nm. PTI Felix fluorescence analysis software was 
used to record the data. Luminescence experiments were carried out using 1 x 1cm 
path length quartz cuvettes with four transparent polished faces. 
Luminescence studies for the nanoparticle samples were carried out using an 
Edinburgh instruments fluorescence system, FLSPM920. The illumination source 
uses a 450 W xenon arc lamp. The detection system used was a Hamamatsu R928 
PMT. The emission monochromator is fitted with two interchangeable gratings blazed 
at 500 nm and 1200 nm. F900 spectrometer analysis software was used to record 




fitted to monoexponential decays using Edinburgh Instruments F900 PC software 
using the exponential tail fit option. 
Lifetimes were alternatively measured using a Continuum Surelite I SSP class 4 
pulsed Nd-YAG laser (10 Hz) as the excitation source using the 355 nm harmonic. 
The signal was collected as a direct output from the PMT to minimise the response 
time of the apparatus. Data were recorded on a LeCroy 9350AM 500 MHz 
oscilloscope which was triggered by the laser, with an average of 500 shots. The 
lifetime data was analysed using Kaleidagraph software (Kaleidagraph 3.51, Synergy 
Software, 2000) for the PC and fitted using a non-linear least-squares iterative 
technique (Marquardt-Levenberg algorithm)  
 
2.5 ICP-OES 
ICP-OES analysis was run at the University of Warwick using a Perkin-Elmer 
5300DV ICP-OES system. PlasmaCal Calibration standards for europium, terbium, 
gadolinium and gold were purchased from SCP science. Concentrations of europium, 
terbium, gadolinium and gold in nanoparticle samples were determined using linear 
calibration curves constructed from purchased standards, with R2 > 0.999 in all cases. 
 
2.6 TEM 
TEM samples were imaged using Jeol 1200EX TEM with an operating voltage of 80 
keV and Gatan multiscan camera. Samples were air-dried onto 200 mesh formvar 
coated copper grids supplied by Agar Scientific. Images were acquired using 





2.7 Luminescence Microscopy 
Cell samples were imaged by luminescence microscopy using an Olympus IX71 
inverted fluorescent microscope with a LUCPLFLN 40 × 0.60 NA objective coupled to 
an Edinburgh Instruments FLS920 spectrophotometer. Excitation was achieved with 
the use of a 450 W Xe lamp and europium emission (>510 nm) was detected by a 
Hamamatsu EMCCD C9100-13. Excitation and emission wavelengths were 
controlled using Edinburgh Instruments v6.8 PC software. Images were acquired 
using CellᴧM 3.2 (Olympus Soft Imaging Solutions GmBH) and post-imaging analysis 
was performed using ImageJ 1.44c. Emission spectra were acquired using 
Edinburgh Instruments F900 v6.8 PC software.  
 
2.8 Particle Sizing 
Particle sizing measurements were made using a Nanosight LM10 system controlled 
by NTA 2.2 software. Dynamic light scattering measurements were acquired using a 
Beckman-Coulter DelsaNano C instrument. 
 
2.9 Circular Dichroism 
Circular dichroism (CD) spectra were obtained on a JASCO J180 spectropolarimeter 
using quartz emission cells with 1 cm path length. Spectra were recorded at an 
internal temperature of 20oC 
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Water soluble gold nanoparticles are coated with peptides
bearing a dithiol surface active group for studies of lanthanide
binding; characteristic red luminescence is observed upon europium
binding to the nanoparticles.
Peptides provide ideal vehicles in the delivery of luminescent
probes in cells for monitoring protein-peptide interactions by
resonance energy transfer, targeting specific protein sites and
visualisation of sensing events. The photophysical properties
of lanthanide ions including large Stokes shift, emission signal
in the visible or near infra-red and luminescence lifetimes in
microsecond to millisecond range, make them ideal probes
for imaging applications in cells.1,2 To this end, lanthanide
binding peptides have been designed with ligating sites either
dominated by the peptide structural organisation3,4 or by
modification with podand and macrocyclic structures.5–8
Based on the similar trends in lanthanide reactivity the same
ligand binding site can be introduced to non-luminescent
lanthanide ions that can be used for MRI imaging,9 NMR
analysis of structural information10 or X-ray structural
elucidation.11 The variety of spectroscopic tools for detection
the incorporation of multiple lanthanide probes can allow
multimodal detection of probes in biological systems.
Nanoparticles can provide an ideal scaffold for the delivery
of multiple probes. Peptide coated nanoparticles and nano-
materials have been of interest for a wide scope of applications
from new biomaterials12 to the introduction of differential
binding to cells.13,14
We have been interested in the delivery of nanoparticles in
cells using lanthanide luminescent and MRI active probes for
imaging.15 We have previously developed lanthanide16–18 and
transition metal complexes19 with surface-active groups for
attachment to nanoparticles and surfaces. In this manuscript
we wish to introduce nanoparticle functionalisation with
peptides bearing dithiol anchoring points and their binding
to lanthanide ions. We chose thioctic acid to introduce
the dithiol attachment as it is known to provide a strong
attachment of receptors for surfaces and nanoparticles.20,21
We chose two peptides ThioALNN and ThioKEESLADDL /
and the latter as it carries a portion of a human NBS1 gene
that interacts with ATM, a member of the phosphatidylinositol
3 kinase family.23 The binding of the peptide to gold citrate
stabilised nanoparticles was monitored by the shift of the
surface plasmon resonance (SPR) band at 521 nm, the
characteristic band of the estimated 13 nm in diameter citrate
coated gold nanoparticles. A 2 nm shift was observed of the
SPR band for the binding of ThioALNN with a slight increase
in intensity, in agreement with the stabilisation observed for
the CALNN peptide binding to gold nanoparticles.22 Addition
of a solution of Eu3+ into the peptide modified nanoparticle
solution, Au-ThioALNN, leads to a decrease in the intensity of
the SPR band with a small red shift (Fig. 1).
All the spectra obtained upon addition of the ThioALNN
peptide and Eu3+ into the nanoparticle solution together with
their binding plots are presented in the Supplementary Info.
The observed shifts are not as large as those obtained for the
binding of Al3+ on CALNN modified gold nanoparticles,24
but it is clear that there is no aggregation. Transmission
Electron Microscopy (TEM) studies of the samples
Au-ThioALNN, EuAu-ThioALNN, and Au-citrate confirm
the uniformity of nanoparticles with diameter around 13–15 nm
(Fig. 2).
The binding of Eu3+ to Au-ThioALNN can be monitored by
luminescence spectroscopy. Addition of a 10 mM solution of
Eu3+ in ml increments into the solution of Au-ThioALNN
leads to a strong increase of the luminescence signal (Fig. 3),
which reaches a plateau indicative of the saturation of the
peptide binding sites on the nanoparticle with Eu3+. The data
are corrected for the residual luminescence signal of Eu3+ in
aqueous solution and have been reproducible. The increase in
the emission intensity can only be attributed to exclusion of
Scheme 1
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water from the lanthanide coordination sphere as a result
of the binding event. The peptide does not possess any
chromophoric units for sensitisation of the europium ion
emission. Addition of Eu3+ to Au-citrate nanoparticles, under
the same conditions, leads to aggregation demonstrated by the
growth of a UV-vis band at 650 nm, while it displays a weak
luminescence signal increase (ESIw). The ThioALNN peptide
forms a 3 : 1 complex with Eu3+ as evidenced by the relative
emission increase upon addition of a solution of Eu3+ to
ThioALNN (ESIw). The steep increase in luminescence
signal indicates a stronger binding than in the case of the
Au-ThioALNN. This may be attributed to the decrease in
binding constant of the multiple charged Eu3+ ions on a single
nanoparticle. The weaker emission increase in EuAu-ThioALNN
is also attributed to the proximity of the luminescent centre to
the gold surface which is known to quench luminescence.17 The
lack of structural freedom of the peptide to wrap around the
lanthanide once bounded to nanoparticle may also contribute
to the overall lower emission signal due to the exposure of the
lanthanide ion to water, which is known to quench the
lanthanide emission signal. This is also supported by the




7F1 in solutions of EuAu-ThioALNN
and EuThioALNN; the emission signal of the hypersensitive
band 5D0 -
7F2 is sensitive to the structural environment
around the lanthanide ion (ESIw).
The binding of the longer peptide ThioKEESLADDL to
the gold nanoparticles was monitored by the shift of the
SPR peak. Although this peptide may be considered more
hydrophobic based on some of the residues, it forms stable
nanoparticles. Following the same conditions as for
Au-ThioALNN, a 1.5 nm shift of the SPR band was observed
upon the formation of Au-ThioKEESLADDL. Addition of
Eu3+ led to a decrease of the SPR band intensity and a red
shift of about 1 nm (ESIw). Although addition of Eu3+ to a
solution of Au-ThioKEESLADDL leads to an increase of
luminescence signal, the relative signal increase is small
(Fig. 4). Monitoring of the ThioKEESLADDL binding to
Eu3+ by luminescence spectroscopy reveals a 1 : 1 binding with
a clear saturation point, indicative of complex formation.
However the binding of Eu3+ to Au-ThioKEESLADDL shows
a different behaviour, indicating a two-step binding event. At low
Eu3+ concentrations, the binding follows the emission increase
of the free peptide binding curve but at higher concentrations, the
binding gets weaker with no saturation plateau (Fig. 4).
The fact that the binding of europium to ThioKEE-
SLADDL showed maximum luminescence signal at 1 : 1
stoichiometry indicates that the peptide wraps around the
lanthanide ion to form a complex. This is clearly not the case
when the peptide is immobilized to the nanoparticle, where the
binding in this case is less specific and the peptide may have
different conformation that does not allow wrapping around
the lanthanide. The luminescence studies are consistently
reproducible. TEM analysis of Au-ThioKEESLADDL shows
a nanoparticle size around 10–15 nm, with few particles
Fig. 1 Selected UV-vis spectra featuring the SPR band of citrate
modified nanoparticles 4.5 nM (—) upon addition of ThioALNN,
0.18 mM in phosphate buffer, (- - -) and Eu3+ 0.52 mM in water (. . .).
Fig. 2 TEM images of Au-ThioALNN (left) and EuAu-ThioALNN
(right).
Fig. 3 Luminescence spectra of Au-ThioALNN upon titration of
Eu3+ 0.036–0.52 mM, [nanoparticle] = 4.5 nM, [ThioALNN] = 0.18
mM, lexc = 280 nm. Insert: Plot of emission increase vs. [Eu
3+].
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around 20 nm, which did not change upon europium binding
(ESIw).
Peptides with dithiol groups for surface attachment are
successfully used to coat Au nanoparticles and lead to
luminescent nanoparticles upon binding to europium in
aqueous solutions. The binding of lanthanides to nanoparticles
is monitored by luminescence spectroscopy, which was used
together with TEM and absorption spectroscopy to characterise
the nanoparticles. We used peptides with no sensitizer groups
to evaluate the lanthanide binding, however there is strong
potential to employ peptide with absorbing groups or external
sensitizer units for further enhancement of the luminescence
signal.
We wish to thank Dr Kysela (Medical School) for the
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Birmingham Science City: Innovative Uses for Advanced
Materials in the Modern World (West Midlands Centre for
Advanced Materials Project 2), with support from Advantage
West Midlands (AWM) and part funded by the European
Regional Development Fund (ERDF).
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Fig. 4 Luminescence spectra of Au-ThioKEESLADDL upon titration
of Eu3+ [nanoparticle] = 4.5 nM, [ThioKEESLADDL] = 0.18 mM,
lexc = 280 nm. Inset: Plot of emission intensity increase vs. [Eu
3+] for
Au-ThioKEESLADDL (x) and ThioKEESLADDL titrations (K).
